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TGFβ signaling is an important regulator in colon cancer. miRNAs regulate TGFβ 
signaling at multiple levels. In this study, through a functional screening, we identified miR-
487b-3p and miR-656-3p, which modulate TGFβ effect in colon cancer cells. Further studies 
revealed that GRM3 and VGLUT3 are their respective targets.   
GRM3, a Metabotropic glutamate receptor in glutamatergic pathway is significantly 
upregulated in majority of human colonic adenocarcinomas tested and colon cancer cell lines. 
Knockdown of GRM3 expression or inhibition of GRM3 activation in colon cancer cells 
reduces cell survival and anchorage-independent growth in vitro and inhibits tumor growth in 
vivo.  Mechanistically, GRM3 antagonizes TGFβ-mediated activation of protein kinase A and 
inhibition of AKT. In addition, TGFβ signaling increases GRM3 protein stability and 
knockdown of GRM3 enhances TGFβ-mediated tumor suppressor function. Since miR-487b-
3p directly targets GRM3, overexpression of miR-487b-3p mimics the effects of GRM3 
knockdown in vitro and in vivo. Expression of miR-487b-3p is decreased in colon 
adenocarcinomas and inversely correlates with GRM3 expression.  
VGLUT3, a vesicular glutamate transporter, is also markedly upregulated in human 
colonic adenocarcinomas and colon cancer cell lines. Knockdown of VGLUT3 expression in 
colon cancer cells reduces cell survival and anchorage-independent growth in vitro and inhibits 
tumor growth in vivo.  Mechanistically, VGLUT3 antagonizes TGFβ-mediated suppression of 
cell survival and clonogenicity by maintaining AKT activation. MiR-656-3p represses 
VGLUT3 expression and mimics the effects of VGLUT3 knockdown in vitro and in vivo. 
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Moreover, expression of miR-656-3p is decreased in colon cancer specimens and inversely 
correlates with VGLUT3 expression.  
This is particularly interesting and important from a therapeutic standpoint because 
numerous glutamatergic signaling inhibitor, many of which have been found unsuitable for 
treatment of neuropsychiatric disorders for reasons such as inability to readily penetrate blood 
brain barriers. Since GRM3 and VGLUT3 are upregulated in colon cancer, but rarely expressed 
in normal peripheral tissues, targeting GRM3 and VGLUT3 with such agents would not likely 
cause adverse neurological or peripheral side effects, making them attractive and specific 
molecular targets for colon cancer treatment. 
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CHAPTER 1：INTRODUCTION 
Colorectal cancer 
Colorectal cancer (CRC) is a common and fatal disease. Nearly 150,000 U.S. residents are 
diagnosed annually with CRC, and approximately one-third of CRC patients die from the 
disease1. CRC begins as a benign adenomatous polyp, which develops into an advanced 
adenoma with high grade dysplasia and then progresses to an invasive cancer. Stage I and II 
tumors which are confined within the wall of the colon are curable by surgery. Combination of 
surgery and adjuvant chemotherapy can increase 3-year disease free survival for up to 73% of 
cases of stage III tumor. But stage IV tumors which metastasize to distant sites are usually 
incurable 2. Therefore, understanding the mechanisms of CRC development and metastasis and 
identifying novel targets for CRC treatment are of importance and challenge. 
TGFβ and cancer 
The transforming growth factor-beta (TGFβ) was discovered more than three decades ago 
and was isolated as a secreted factor from sarcoma virus-infected cells 3 4.TGFβs are 25-kDa 
cytokines that play a pivotal role during mammalian development and act as a regulator of 
wound healing, fibrosis, angiogenesis and differentiation of the cells. More than 40 different 
members have been identified in this family. In mammalian cells, there are three TGFβ isoforms 
(TGFβ1, TGFβ2, and TGFβ3), among which TGFβ 1 is the most abundant and universally 
expressed isoform 5. TGFβ signaling is initiated by TGFβ binding to TGFβ receptor type II 
(TGFβRII) which binds and activates TGFβ receptor type I (TGFβRI). Activated TGFβRI 
subsequently phosphorylates SMAD2 and SMAD3 at the carboxyl terminal serines. Following 
phosphorylation, SMAD2 and SMAD3 form heteroligomeric complexes with the co-SMAD, 
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SMAD4, and accumulate in the nucleus. SMAD proteins recognize DNA sequence CAGAC, 
called SMAD binding element (SBE). They also bind to some other GC rich sequences, but the 
binding for those DNA sequences is weak. SMADs usually associate with other transcriptional 
cofactors to achieve specific regulation of TGFβ-mediated transcription response (Fig 1.1) 6. 
Other members in the TGFβ superfamily, such as bone morphogenetic proteins (BMPs), active 
their signaling through other R-SMAD proteins (such as SMAD1 ,5 and 8) 7.  
  
Fig 1.1  
 
Figure 1.1. Schematic diagram of TGFβ signaling pathway.   
On the cell membrane, TGFβ binds to the receptor II which in turn attracts and 
phosphorylates TGFβ receptor I. Activated receptor I phosphorylates Smad2/3 which recruit 
smad4 in the nuclear. In the nucleus, Smad complex bind to the cofactor and regulate target 
genes engaged in both tumor promotion and tumor repression. 
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TGFβ/SMAD signaling is regulated by multiple mechanisms to maintain tightly controlled 
TGFβ response. SMAD7 is the first described inhibitory SMAD which negatively regulates 
TGFβ response by preventing access of SMAD2/3 to the kinase domain of receptor I 8,9.SMAD 
7 also recruits phosphatases and ubiquitin ligases (smurf1/2) to the active TGFβ receptor I to 
terminate TGFβ signaling 10. Another inhibitory SMAD, SMAD6, competes with SMAD4 for 
binding to receptor activated SMAD17.  
In addition to mediating the transcription of its target genes, TGFβ can also activate 
GTPases (Rac1, Cdc42, RhoA and Ras), MAP kinases (JNK, p38 MAPK and ERK1/ERK2), 
growth and survival promoting kinases (PI3K, AKT/PKB and mTOR) and tyrosine kinases 
(FAK, Src and Abl) in different cell context 11. 
In normal condition, TGFβ is released by blood platelets and various stromal components. 
TGFβ is frequently present in tumor environment. Tumor infiltrating cells such as leukocytes, 
macrophages, and bone marrow-derived endothelial, mesenchymal, and myeloid precursor 
cells can secret TGFβ, tumor cells themselves and tumor stroma cells are sources of TGFβ too 
12. In tumors, TGFβ is a potent inducer of growth inhibition at early stages of tumorigenesis. 
For example, when the tumor is still benign, TGFβ acts directly on tumor cells to suppress 
tumor outgrowth by inducing expression of CDK inhibitors p15INK4B and/or p21CIP1. The 
induction of p15 and p21 by TGFβ is through SMADs and other transcriptional factors like 
FoxO forkhead and Sp1 13,14. Suppression of oncogenes like c-Myc and ID family of helix-loop-
helix transcription factors (ID1,ID2,ID3) is also observed in many cell types that are growth 
inhibited by TGFβ 15,16. TGFβ has also been shown to induce apoptosis in epithelium, liver, 
immune system and tumors 17. In hepatocarcinomas, TGFβ induces apoptosis by increasing the  
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interaction of Daxx protein with TGFβ RII, which further actives JNK and Fas-mediated 
apoptotic pathways 18. In many types of cells, TGFβ induces pro-apoptotic Bcl-2 family 
members, Bmf and Bim, which activate Bax and induce apoptosis 19. In some other types of 
cells, TGFβ suppresses the expression of anti-apoptotic proteins Bcl-XL and Bcl-2 19. In 
immune cells, TGFβ shows a strong pro-apoptotic effect by inducing expression of Src 
homology 2 domain-containing 5’ inositol phosphatase (SHIP), which causes cell death of 
immune cells 20. In colon cancer cells, TGFβ antagonizes the survival pathways through 
downregulation of PI3K-AKT 21 and Bcl-XL 22. In addition, TGFβ prevents cellular 
immortalization by regulating the expression of human telomerase reverse transcriptase 
(hTERT) in both normal and cancer cells 23.  
Mutations in the TGFβ signaling pathway occur in at least half of colorectal cancer, 
commonly inactivating TGFβ RII, SMAD2, SMAD3 or SMAD4, which leads to its inability to 
inhibit cell growth and induce apoptosis24-26.  Mutations of  TGFβ RII lead to the formation 
of truncated or kinase inactive mutant forms of the receptor 27. Mutations of SMADs are mostly 
due to deletions, frameshift, nonsense and missense mutations 28. Overexpression of SMAD 
repressors also contributes to the inhibition of SMAD signaling. For example, SnoN, Ski, and 
inhibitory SMAD family members SMAD7 have been found to be overexpressed in many 
different types of cancers 29. Besides the change on TGFβ receptors and SMADs, the alteration 
of other signaling pathways can also affect TGFβ signaling during tumor progression. For 
instance, the Ras-Raf-MAPK pathway regulates the activation of SMAD3 by regulating its 
phosphorylation 30.  
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As tumor progresses, the cytostatic effects of TGFβ are often lost, and instead, TGFβ is 
shown to stimulate tumor progression by inducing epithelial to mesenchymal transition (EMT), 
stimulating angiogenesis and immunosuppression 31. In some cancers, TGFβ secretion is 
correlated with high tumor grade and metastasis 32. As mentioned above, TGFβ secreted by 
tumor cells and tumor stroma cells has a huge effect on immune system. It inhibits expression 
and activation of interleukin-2 and its receptors and blocks its stimulation on T cells 33. TGFβ 
also exerts inhibitory effect on proliferation and differentiation of T lymphocytes, lymphokine-
activated killer cells, nature killer cells, neutrophils, macrophages and B cells 34. It has been 
shown that TGFβ inhibits the expression of tumor cell surface major histocompatibility 
complex class II antigen in a SMAD3 dependent manner 35. Taken together, TGFβ in the tumor 
environment helps tumor cells to escape host immunosurveillance and contributes to tumor 
progression.  
Angiogenesis is essential to allow blood vessels to deliver oxygen and nutrients to tumor 
cells. TGFβ signaling has been shown to be correlated with increased micro vessel density in 
many types of cancers 36 37.The most common role of TGFβ on angiogenesis is to stimulate the 
expression of vascular endothelial growth factor(VEGF) and connective tissue growth factors 
(CTGF) 38,39. In addition, the matrix metalloproteinase (MMPs) induced by TGFβ allows 
endothelia cells to be released from the basement and migrate to the tumor site 40.  Moreover, 
TGFβ represses the expression of angiopoietin-1 to allow the tumor-associated blood vessels 
to become more permeable 41.  
EMT is an important process that cancer cells use to migrate and invade  42. The role of 
TGFβ on EMT has been well characterized. The TGFβ-SMADs canonical pathway 
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transcriptionally activates EMT regulatory factors, such as SNAIL, SLUG, ZEB-2 and TWIST, 
resulting in the loss of epithelial cell polarity and the increase of migration and invasion 43. 
TGFβ induced EMT changes the profile of adhesion molecules and promote cancer cells to 
detach from their primary site and disseminate throughout the stroma.  
TGFβ significantly affects colon cancer biological behaviors. Moderate and well 
differentiated colon tumors were growth inhibited by TGFβ, while, metastatic colon tumors 
responded to TGFβ by invasion and proliferation44 . In the well differentiated colon tumors, 
TGFβ activates its downstream targets which are important cell cycle checkpoint genes, 
including p21, p17 and p15 44 . TGFβ also interacts with PI3K-AKT pathways and induce 
apoptosis in colon cancer cells 21. TGFβ RII mutation is the most common alteration in colon 
cancers45. Loss of TGFβ RII function grants a growth advantage for cancer cells by cooperating 
with mutant Kras and Wnt signaling 46. SMAD4 is also a frequently mutated gene in TGFβ 
pathway. SMAD4 is a key mediator for TGFβ induced antiproliferative response, but TGFβ 
induced EMT is not dependent on SMAD447. This indicate that loss of SMAD4 function might 
be an important event during colon cancer progression.  
MiRNAs  
MicroRNAs (miRNAs) are approximately 19–25 nucleotides long (with an average of 22 
nucleotides), noncoding RNA molecules that post-transcriptionally regulate gene expression by 
binding either to the 3’untranslated regions (3’UTR), 5’untranslated regions (5’UTR) or the 
coding sequence of protein-encoding mRNAs 48. The region at the 5’ end of miRNAs that spans 
from nucleotide position 2 to 7 is termed the 'miRNA seed'. It is crucial for target recognition. 
The downstream nucleotides of miRNA (particularly nucleotide 8 and less importantly 
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nucleotides 13–16) also contribute to base pairing with the targets 49. miRNAs regulate 
approximately 30–50% human genes and majority of genetic pathways.  miRNA genes are 
transcribed by RNA polymerase II (Pol II). The long primary transcript has a local hairpin 
structure where miRNA sequences are embedded. Majority of human miRNAs are encoded by 
introns of noncoding or coding transcripts, but some miRNAs are encoded by exonic regions. 
The transcription of miRNAs is controlled by RNA Pol II associated transcription factors and 
epigenetic regulators such as P53, MYC and other DNA/RNA binding proteins 50. Following 
transcription, the primary miRNAs are processed through several steps to become mature 
miRNAs. The maturation of primary miRNAs is initiated by a nuclear RNase III, called Drosha, 
which forms a microprocessor with a cofactor DGCR8 and crops the stem–loop to release a 
small hairpin-shaped RNA of ~65 nucleotides in length (pre-miRNA) 51. Pre-miRNAs are 
exported to the cytoplasm after processed by Microprocessor. The protein exportin 5 (EXP5; 
encoded by XPO5) forms a transport complex with GTP-binding nuclear protein RAN•GTP, 
which exports the pre-miRNA out of the nuclear 52. In the cytoplasm, pre-miRNAs are cleaved 
by RNase III type endonuclease called Dicer, liberating a small RNA duplex 53. The small RNA 
duplex is subsequently incorporated into an AGO protein to form an effector complex called 
RNA-induced silencing complex (RISC). As a result, the passenger strand is quickly removed 




         
Fig 1.2  
 
Fig 1.2. Biogenesis of miRNAs. 
Pri-miRNA are transcribed by RNA polymerase II, and processed to pre-miRNA in the nucleus. 
RNA splicing is also a source of pre-miRNAs. Pre-miRNAs are transported into the cytosol, 
where they are pressed by Dicer to become mature miRNAs and regulate target gene expression.  
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miRNAs and cancer 
A significant number of miRNAs are located at genomic regions linked to cancer56. The 
first evidence of aberrant miRNA expression in human cancers was described in B-cell chronic 
lymphocytic leukemia. A chromosomal deletion at the 13q14 locus resulted in the loss or 
reduction of miR-15 and miR-16 expression，which are inhibitors of oncogenetic protein BCL-
2 57. miRNA expression can be altered through different mechanisms, including chromosomal 
abnormalities, epigenetic changes, mutations and single nucleotide polymorphisms (SNPs), and 
defects in the miRNA biogenesis machinery 58. Many miRNAs reside at fragile site of the 
chromosome where sister chromatin exchange, translocation, deletion, amplification happen 
very frequently. miR-143 and miR145 has been found to be decreased in B cell chronic 
lymphocytic leukemias and lung cancers, while miR-19-92, located at chromosome 13q31, is 
found overexpressed due to chromosomal amplification in those cancers 57,59. In addition, 
epigenetic changes affect miRNAs expression as well. MiR21, miR-203 and miR-205 were 
found to be overexpressed in ovarian carcinomas through hypomethylation mechanism 60.  On 
the contrary, decreased miR-124a expression in colon, breast, and lung cancers was attributed 
to DNA hypermethylation 61.  
miRNAs have been demonstrated to function as oncogenes or tumor suppressors 62. The 
overexpression of miR-155 is associated with several types of lymphomas. Transgenic mice 
overexpressing miR-155 developed a preleukemic lymphoproliferative disease that progressed 
to B-cell leukemia and high grade lymphoma 63. Down regulation of some miRNAs might be 
advantageous for cancer cells. For example, miR-17 was found to be downregulated in breast 
cancers and ectopic expression of this miRNA reduced cancer cell proliferation 64.   
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In cancers, miRNAs affect cell growth, proliferation, apoptosis, invasion and metastasis 
by regulating genes in different signaling pathways 65. miR-221/222, miR-17-92 and miR-106-
25 have been reported to target negative cell-cycle regulators and promote cancer cell 
proliferation 66. miR15a/16 was shown to target cyclin D1, cyclin D3, cyclin E1 and CDK6, 
and their downregulation increased expression of multiple cell cycle-promoting genes 67.  
Furthermore, the accumulated data on miRNA expression in tumors demonstrate that 
miRNAs are promising candidates for prognostic and/or diagnostic markers. It has been shown 
that the miR-222, miR-106a, and miR-17-92 cluster is associated with the degree of 
differentiation of  hepatocellular carcinomas 68. High miR-21 expression was present in colon 
adenomas and in tumors with more advanced TNM staging 69. Another study showed that high 
level of MiR-92a was associated with decreased survival in patients with small-cell lung cancer 
70. And the expression of MiR-210 was found to be associated with poor clinical outcome of 
breast cancer.71  
MiRNAs and TGFβ  
miRNAs and the TGFβ pathway are tightly interacted with each other. Transcription of 
primary miRNAs can be dynamically regulated in response to stimulation of many growth 
factors including TGFβ 72. TGFβ promotes miRNA processing by regulating miRNA DROSHA 
microprocessor complex in a SMAD-depend manner 73.  
Upon TGFβ treatment, alterations in expression of numerous miRNAs have been reported 
in different types of cells. Expression of the miR-200 family (miR-200a, miR-200b, miR-200c, 
miR-141 and miR-429) and miR-205 was markedly downregulated upon TGFβ treatment. In 
addition, TGFβ suppresses expression of many other miRNAs, miR-145, Let-7d, miR-155, 
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miR-34, miR-27b, miR-29. On the contrary, there are quite a few miRNAs whose expression 
is upregulated by TGFβ, for example, miR-21, miR-142, miR-146, miR17/92, etc. 74.  
The TGFβ pathway is regulated by miRNAs at multiple levels. Expression of most, if not 
all, members of the canonical TGFβ signaling pathway may be influenced by miRNAs. The 
miR-23b cluster (including miR-23b, miR-27b and miR-24-1) suppress TGFβ signaling by 
downregulating expression of SMAD3, SMAD4, and SMAD5 75. In the heart, downregulation 
of miR-133 and miR-590 enhances TGFβ signaling through TGFβ RI and RII 76. In the liver, 
miR-21 enhances TGFβ signaling by targeting the negative regulator SMAD7 77. While miR-
26a was found to target SMAD1, miR-141 and miR-200a directly inhibit TGFβ RII expression 
in rat proximal tubular epithelial cells 78,79. 
miRNAs can also downregulate TGFβ target genes, which ultimately affects the outcome 
of TGFβ effect. The miR-106b/25 cluster (miR-106b, miR-93 and miR-25) was reported to 
interfere with the tumor suppression effect of TGFβ by targeting the cell cycle inhibitor 
p21Waf1/Cip1 and the pro-apoptotic protein BCL2L11 (BIM) in gastric cancer 80. BIM is also 
targeted by miR-17/92 in B cells 81.  
Glutamate and its signaling 
Glutamate is a nonessential amino acid, a major bioenergetic substrate for proliferating in 
normal and neoplastic cells. In the nervous system, glutamate is one of the key 
neurotransmitters and it participates in several physiological processes such as learning, 
memory, behavior and long-term potentiation and synaptic plasticity 82,83. Glutamate has been 
shown to regulate proliferation, migration and survival of neuronal progenitors and immature 
neurons during development of nervous system 84-86. Moreover, its function in regulating cell 
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proliferation and migration has also been described in human brain, breast, lung and colon 
cancer cell lines 87. Recent studies have demonstrated that human cancer cells release high level 
of glutamate 88, which triggers invasive tumor growth 89. Serum glutamate level was found 
correlated with Gleason Score in prostate cancer patients 90. An analysis of freshly frozen 
human samples also demonstrated that glutamate level was strikingly increased in chronic 
pancreatitis and pancreatic ductal adenocarcinoma tissues compared to normal pancreatic tissue 
91.  
Glutamate is stored in synaptic vesicles and released upon stimulation 92. In mammals, 
glutamatergic system is maintained by a group of glutamate transporters, which include two 
super families: the excitatory amino acid transporter (EAATs) located at the plasma membrane 
and the vesicular glutamate transporters (VGLUTs) located at the membrane of synaptic 
vesicles. The family of VGLUTs is comprised of three highly homologous proteins VGLUT1-
3. They transport glutamate from cytoplasm into the vesicles to be released 93. Expression of 
VGLUTs is mostly complementary with limited overlap. VGLUT1 and VGLUT2 are mainly 
expressed in glutamatergic neurons 94 whereas VGLUT3, encoded by SLC17A8 gene, is present 
in a limited number of glutamatergic neurons in multiple brain regions and in a population of 
symmetrical synapses 95. VGLUT3 is the only vesicular glutamate transporter detected in the 
dendrites of striatal neurons 96. In addition to CNS, VGLUTs can be found in peripheral nervous 
system (PNS) and in the glutamate-secreting non-neuronal cells of different organs, such as the 
pineal gland, islets of Langerhans, intestine and stomach, bone and testes 97-100.  
Glutamate signaling is initiated when glutamate binds to different type of receptors. 
Glutamate receptors are divided into two groups, ionotropic glutamate receptors (iGluR) and 
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metabotropic glutamate receptors (mGluR) 101. iGluRs are quaternary ligand-gate ion channels 
that allow cation influx upon glutamate binding101. Based on structural similarities iGluRs are 
classified into three groups, N-methyl-D-aspartate (NMDA) receptor, a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor, and kainate receptor subfamilies. mGluRs 
belong to the superfamiliy of G-protein coupled receptors, they are classified into three 
subgroups. mGluR1 and mGluR5, coupled to the phospholipase C through Gq G-protein, 
belong to group I; group II consists of mGluR2 and mGluR3, whereas group III comprises of 
mGluR4, mGluR6, mGluR7 and mGluR8, both of which are negatively coupled to adenylate 
cyclase through Gi G-protein 102.  
iGluRs have four conserved domains, including the extracellular amino-terminal (ATD), 
ligand-binding (LBD), transmembrane (TMD), and intracellular carboxy-terminal (CTD) 
domains. Glutamate or agonist binds to the LBD, resulting in a conformational change of the 




         
Fig 1.3  
 
Figure 2.3. iGluR structure and activation.  
iGluRs share the same basic structure: the N terminus (N), the amino terminal domain 
(ATD), the ligand binding domain (LBD), the four transmembrane domains (TMD; numbered 
1-4) and the C-terminal domain (CTD). Panel A shows the resting conformation of iGluR. The 
entire protein consists 4 subunits, two of them can create a channel through the plasma 
membrane. When glutamates bind to LBD (Panel B), a conformational change in TMD domain 
1 causes opening of the channel where Ca2+ passes into the cell by diffusion. 
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All mGluRs share a basic structure which includes a large extracellular ATD at the N-
terminus, a cysteine-rich domain (CRD), a seven alpha-helical TMD and an intracellular CTD. 
GluRs function when dimerized at the CRD domain, with two glutamate molecules binding to 




Figure 1.4 mGluR structure and conformational activation. 
mGluR family members share the same basic structure: the N terminus (N), the amino 
terminal domain (ATD), the cysteine rich domain (CRD), the seven transmembrane domains 
(TMD; numbered) and the C-terminal domain (CTD). Panel A shows the resting conformation 
of mGluR1a. Cysteine residues in the CRD aid in dimerization, as indicated by the S-S bond. 
When glutamate bind to ATD domain (Panel B), a conformational change in the ATD causes 
activation of bound G proteins. 
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Group I mGluRs couple to Gq/G11 and activate phospholipase Cβ, resulting in the 
hydrolysis of phosphotinositides and generation of inositol 1,4,5-trisphosphate (IP3) and 
diacyl-glycerol. This classical pathway leads to calcium mobilization and activation of protein 
kinase C (PKC) 104. recently, it is been recognized that this receptor can activate many other 
protein kinase pathways such as casein kinase 1, cyclindependent protein kinase 5, Jun kinase, 
components of the mitogen-activated protein kinase/extracellular receptor kinase (MAPK/ERK) 
and the mammalian target of rapamycin (MTOR)/p70 S6 kinase pathway 105-109. Group II and 
group III receptors are coupled with Gi/0 which inhibits adenylyl cyclase. In addition, they have 
been shown to activate MAPK and PI3K-AKT pathways 107.  
In recent years, many studies have shown that mGluRs are the predominant mediators of 
glutamatergic signaling in cancers 103. Function of mGluRs in cancer progression is first studied 
in tumors of central nervous system 110. Many evidences have also shown that mGluRs are 
involved in other types of cancers 111-114. Both group I and II mGluRs have been implicated to 
play a role in glioma. Inhibiting mGluR1 inhibits U87 glioma cell growth and induces apoptosis 
both in vitro and in vivo by mitigating the activation of the PI3K/Akt/mTOR pathway 115. 
Another study showed that an mGluR2/3 antagonist suppressed glioma cell growth and removal 
of the antagonist restored cell growth 113. In addition, mGluRs are also studied in other non-
neuronal cancers. Chen group found that the aberrant expression of mGluR1 is the driving force 
of melanomagenesis in transgenic mouse models, and mGluR1 mediated activation of the 
MAPK and PI3K/AKT pathways is critical in melanoma pathogenesis 116. An exon capture 
sequencing of GPCRs study showed that in malignant melanoma specimens, somatic mutations 
of mGluR3 (GRM3) (E767K, S610L,G571E and E870K) can regulate the phosphorylation of 
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MEK1/2 and induce micro metastasis of  melanoma 117. In colorectal cancer, mGluR4 has been 
found to be correlated with 5-Fu resistance and poor prognosis 118. The increasing evidence is 
showing that glutamate signaling could be a potential target for cancer treatment.    
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CHARAPTER 2：MATERIAL AND METHODS 
Cell lines and reagents  
The immortalized human colon epithelial cells (HCEC) were provided by Dr. Jerry 
Shay119. The human colon cancer HCT116, RKO, FET, CBS, HCT116b and GEO cells were  
cultured in McCoy’s 5A medium (Sigma) with 10 ng/ml epidermal growth factor (EGF), 20 
µg/ml insulin, and 4 µg/ml transferrin 120. When subjected to GFDS, cells were cultured in 
medium without EGF, insulin and transferrin. Cells were maintained at 37oC in a humidified 
incubator with 5% CO2 and checked periodically for mycoplasma contamination. TGFβ and 
LY341495 were obtained from R&D Systems. The miR-656-3p and miR-487b-3p inhibitor 
were obtained from and Qiagen Inc. respectively. Antibody information is included in 
Supplemental Table 2.1.   
Western blot analysis, RT-PCR and Q-PCR assays  
Whole cell lysates were prepared in RIPA buffer (1% Triton X-100, 1% sodium 
deoxycholate, 0.1% SDS, 150 mM NaCl, 10 mM Tris–HCl, pH 7.5, 5 mM EDTA and a protease 
inhibitor cocktail from Sigma-Aldrich). Equivalent amounts of protein were separated by SDS–
PAGE and transferred to a PVDF membrane (Millipore). Proteins were detected using an 
enhanced chemiluminescence system (Amersham Biosciences).  
Expression of miR-656-3p and miR-487b-3p were determined by miScript primer assays 
and miScript SYBR® Green PCR Kit from Qiagen Inc. RNU6-2 was used as an endogenous 
reference gene. 
Q-PCR analysis of GRM3 mRNA was performed using SYBR Green qPCR Mastermixes 
(Qiagen). The primer sequences are GCACCTCAACAGGTTCAGTGT-F and 
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TGGTGGAGTCGAGGACTTCC-R.  
Expression of VGLUT1-3 and GRM2-4 mRNA was determined by RT-PCR analysis. The 
primer sequences are included in Table 2.2.  
Apoptosis assays  
Apoptosis was detected using a DNA fragmentation ELISA kit (Roche). DNA 
fragmentation ELISA assays were performed according to manufacturer’s protocol. Briefly, 
cells were seeded in 96-well plates and subjected to growth factor deprivation stress (GFDS) 
or treated with TGFβ. The cells were stained with MTT to determine cell numbers or lysed for 
the ELISA assays to determine apoptosis. The relative apoptosis was determined by dividing 
ELISA values by MTT values of each sample.  
Soft agarose assays  
Cells were seeded in culture medium containing low melting point agarose (Thermo 
Scientific) at a density of 3,000 cells per well in 6-well plates. Two weeks later, colonies were 
stained with 1% iodonitrotetrazolium violet (Sigma-Aldrich). Visible colonies were counted.  
Plasmids construction and lentiviral infection  
The miR-656 and miR-487b precursor-expressing lentiviral vector, pCDH-CMV, was from 
SBI. ShRNAs targeting GRM3 or VGLUT3 were cloned into FSIPPW lentiviral vector. The 
targeting sequences of VGLUT3 are VGLUT3 sh2 5-GCTGTAGGATTTAGTGGCTTCGCTA-
3, VGLUT3 sh3 5-CCCAGAATTGTGAAGTCCAGAAGAA-3. pCDF1-VGLUT3 was 
purchased from Harvard plasmid, provided by David E Root group. Clone: HsCD00421938, 
PMID 21706014. The targeting sequences of GRM3 was described previously 117 : sh1, 5-
CAGAACATGGAAATAACCATT-3and sh2, 5- GCCTGTTTCCTATTAACGAAA-3 
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SMAD2 shRNA and SMAD3 shRNA are 5-GCACTTGCTCTGAAATTTG-3 and 5-
GGATTGAGCTGCACCTTGAATG-3 respectively. PKACα shRNA was described 
previously121 . pCDF1-GRM3 WT was a gift from Yardena Samuels (Addgene #31798). 
293 packaging cells were co-transfected with pPackH1 packaging plasmid mix (SBI) and 
the lentiviral vectors using Fugene HD (Promega). Viruses were harvested 48 hours later and 
used to infect target cells.  
Luciferase Assays  
The predicted miR-656-3p recognition sites in the 3’UTR of VGLUT3 and corresponding 
mutated sequences were synthesized and cloned into psiCHECK™-2 (Promega) downstream 
of Renilla reporter gene. The predicted miR-487b-3p recognition sites in the 3’UTR of GRM3 
was synthesized and cloned in the same vector. The reporter was transfected into cells and 
luciferase activity was measured 48 hrs later using Dual-Luciferase Reporter Assay (Promega). 
Values were normalized with firefly luciferase activity.  
In vivo xenograft model  
Animal experiments were approved by University of Nebraska Medical Center (UNMC) 
Institutional Animal Care and Use Committee. CBS cells (4 x 106) expressing a control vector, 
miR-487b precursor, a scrambled shRNA or GRM3 shRNAs and HCT116 cells (2 x 106) 
expressing a control vector, miR-656 precursor, a scrambled shRNA or VGLUT3 shRNAs were 
injected into the flank of 4-6 week old male athymic nude mice on both sides (Harlan 
Laboratories). There were 8 mice and 16 tumors in each experimental group. Tumor volumes 
(V) were calculated by the formula V = W2 × L × 0.5, where W represents the largest tumor 
diameter and L represents the next largest tumor diameter. Upon termination of the experiments, 
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tumors were dissected out and photographed on the same scale.  
IHC staining of GRM3/VGLUT3 in xenograft tumors and human patient samples  
Human sample study was performed with the approval of Institutional Review Board. 
TMAs consisting of triplicates of 1 mm cores of colon adenocarcinomas and adjacent normal 
tissues of patients treated at UNMC in 2008 and 2009 were obtained from tissue core.  
IHC staining was performed in paraffin slides using Novolink™ Min Polymer Detection 
System (Leica) following manufacture’s instruction. Briefly, slides were subjected to antigen 
retrieval using Novocastra Epitope Retrieval Solutions, pH6, followed by incubation with an 
anti-VGLUT3 or anti-GRM3 antibody overnight at 4 °C. Slides were developed with DAB 
after incubation with Novolink polymer. Finally, slides were counterstained with hematoxylin. 
The slides were scanned with IScan Coreo (Ventana Medical Systems, Inc).  The staining 
intensity of epithelial cells was quantified with Imagescope Software (Aperio Technologies, 
Inc.). 
TUNEL assay and Ki67 staining  
Formalin-fixed paraffin embedded (FFPE) tissue blocks of xenograft tumors were stained 
for Ki67 using Novolink™ Min Polymer Detection System (Leica). TUNEL staining was 
performed using Trevigen In Situ Apoptosis Detection Kit following manufacturer’s 
instruction. Three tumors from each group were analyzed. Ten histologically similar fields were 
randomly selected from each slide for analysis. Apoptosis and proliferation of tumor cells was 
determined quantitatively by counting the numbers and calculating the percentage of positively 
stained cells for TUNEL and Ki67 at 20x magnification respectively. 
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In Situ hybridization 
The double DIG labeled probe for miR-487b-3p and miR-656-3p and hybridization kit 
were purchased from Exiqon. Hybridization was performed following Exiqon’s protocol. 
Briefly, tissues were deparaffinized and digested with proteinase K (15 μg/ml; Exiqon) for 10 
min at 37°C. Slides were incubated in hybridization buffer with 40 nM probe (miR-487b-3p 
5DigN/AAGTGGATGACCCTGTACGATT/3Dig_N/, miR-656-3p 5DigN/ 
AGAGGTTGACTGTATAATAT /3Dig_N/) in a humidified chamber at 45°C overnight. Slides 
were then blocked with anti-digoxigenin-alkaline phosphatase antibodies (Roche) at 1:800 
dilution for 1 hr and stained with AP substrate (NBT/BCIP tablet, Roche) at 30°C for 6 hrs. The 
nuclei were counterstained with nuclear fast red (Sigma). The slides were scanned with IScan 
Coreo (Ventana Medical Systems, Inc). The staining intensity of epithelial cells was determined 
using Image-Pro Plus (Media Cybernetics. Inc).  
Transwell assays 
Cells were seeded onto the upper surface of 8-µm pore, 6.5 mm polycarbonate filters 
(Corning Costar Corp.) in medium without growth factors or serum, allowed to migrate towards 
medium with 10% FBS for 18 hrs and stained with MTT. The cells on the upper surface of the 
filter were removed with a cotton swab, and those migrated to the underside were dissolved in 
DMSO. Absorbance was read at 570 nm. 
Statistical analysis  
Statistical analyses were performed using Bonferroni two-sided t-test, two-way ANOVA 
or Student’s t-test. *P < 0.05, ** P < 0.01, *** P < 0.001. 
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Table 2.1 Antibodies 
Antibodies Companies Western blots IHC 
anti-PARP Cell Signaling # 9542S 1:1000  
anti-pAKT S473 Cell Signaling # 9271S 1:1000  
anti-CREB Cell Signaling # 9197S 1:1000  
anti-pCREB Cell Signaling # 9198S 1:1000  
anti-AKT Cell Signaling # 4691S 1:1000  
anti-SMAD2 Cell Signaling # 5339S 1:1000  
anti-SMAD3 Cell Signaling # 9523S 1:1000  
anti-pSMAD1/5 Cell Signaling # 9516S 1:1000  
anti-ERK Santa Cruz sc-514302 1:1000  
anti-pERK Santa Cruz sc-7383 1:1000  
anti-Actin Thermo Scientific MA5-15739 1:5000  
anti-GAPDH Thermo Scientific MA1-16757 1:5000  
anti-Ki67 Thermo Scientific MA5-14520  1:1000 
anti-GRM3 Alomone labs AGC-012 1:1000 1:500 






         










  5-TGACAAGAGACCCACACTTAGAC-3 
VGLUT2 5-TGGCAACCACCTCCTTTTGT-3 
  5-CATAGTGGACTAGGGCAGCG-3 
VGLUT1 5-CAGGAAGGCGCGAGACATTGGAG-3 
  5-AGTGAACACGGGCTGCTGAAGGGA-3 
VGLUT3 sh2 GCTGTAGGATTTAGTGGCTTCGCTA 
VGLUT3 sh3 CCCAGAATTGTGAAGTCCAGAAGAA 
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CHAPTER 3: MIRNA LIBRARY SCREENING. 
Accumulating reports have shown that miRNAs are important players in many types of 
human cancers. TGFβ is an important regulator in colon cancer. Functional genetic screening 
is a systematic, non-biased and powerful approach for gene discovery. Here we used a 
microarray based miRNAs screening approach and identified some nova miRNAs that involved 
in TGFβ function in colon cancer cells.  
The functional screening is described in Figure 3.1. A library of 560 miRNAs expression 
vectors was introduced into FET cells, after recovery from infection, cells were seeded into 
10cm dish at a density of 9000 cell per well in the presence of 10ng/ml TGFβ (eight replicates). 
The empty vector-transduced cells were plated at the same density as a negative control, and 
TGFβ response defect FET Dominant negative RII cells as positive control. Two weeks after 
treatment, colonies were harvested and a second round of TGFβ selection was performed. By 
the end of two rounds selection, survived cells were harvested and genome DNA was extracted 
from each plate. The integrated miRNAs were amplified from genomic DNA by PCR using 
specific primers. The PCR product was purified and labeled with cy3 as end sample. PCR 
product from vector control cells which underwent two round of colony formation without any 
TGFβ treatment will be labeled with cy5 as initial sample. Equal amount of initial sample and 
end sample were mixed and hybridized to the customized microarray. Microarray data was 
analyzed by Agilent, the average fold change of each miRNAs compared to control was 
calculated, p value was calculated by Student t test. As shown in Table 3.1, some miRNAs are 
enriched while some others are significantly dropped out after TGFβ selection. We then focused 
on the dropped out miRNAs which can potentially make FET cells sensitive to TGFβ for future 
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studies. 
We then used DIANA miPath to look for the common pathways that are regulated by the 
miRNAs we identified. Interestingly we found that glutamatergic pathway is highly regulated 
by those miRNAs. Many studies have shown the importance of glutamatergic pathway in 
cancers. GRM3 and VGLUT3 are two important components in glutamatergic pathway, they 
are also targets of the miRNAs we identified. So, we hypothesize that, GRM3 and VGLUT3 
might be very important regulators of colon cancer tumorigenesis and TGFβ function.  
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Figure 3.1 workflow of miRNAs screening in FET cells using TGFβ. 
Table 3.1 
 
Table 3.1 List of increased and decreased miRNAs from screening 
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CHAPTER 4 ：THE MIR-487B-3P/GRM3/TGFΒ SIGNALING AXIS IS AN 
IMPORTANT REGULATOR OF COLON CANCER TUMORIGENESIS 
INTRODUCTION  
Glutamate functions as a major excitatory neurotransmitter in mammalian central nervous 
system. Glutamate signaling is mediated by two classes of glutamate receptors, ionotropic and 
metabotropic receptors 122. Metabotropic receptors (mGluR), a group C family of G-protein-
coupled receptors (GPCRs), consist of eight members, classified into three subtypes 123,124. 
Group I receptors (mGluR1 and 5) are coupled to phospholipase C leading to activation of 
protein kinase C, whereas group II (mGluR2 and 3) and group III (mGluR4, 6, 7 and 8) 
receptors are negatively coupled to adenylyl cyclase, inhibiting production of cyclic AMP 
(cAMP) 102. Although glutamatergic system is mainly restricted to the CNS, expression of 
functional glutamate receptors has been reported in non-neuronal peripheral cells such as skin 
and pancreatic islets 125,126. Furthermore, studies have revealed that glutamate signaling is 
dysregulated and may play a role in cancer 118,127. 
GRM3 is the gene encoding mGluR3, which is frequently mutated in melanoma. Mutant 
GRM3 selectively activates MEK, leading to increased anchorage-independent growth and 
migration117. Activation of GRM3 has been reported to BMP signaling and sustain tumorigenic 
potential of glioma-initiating cells128. Pharmacological blockade of GRM3 reduced growth of 
glioma cells in vitro and in vivo 113,129. These studies suggest that GRM3 plays a role in cancer 
and could be a potential target for cancer treatment. 
TGFβ signaling plays a dual role in cancer. While studies show that TGFβ promotes 
metastasis and is associated with worse prognosis130,131, others demonstrate that it suppresses 
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tumorigenicity and metastasis 132-135 and that loss or reduction of TGFβ signaling is associated 
with development of metastasis 136,137. In genetically engineered mouse models, inactivation of 
TGFβ signaling increases malignancy and invasiveness of intestinal tumors of Apc mutant mice 
138-141.  
miRNAs are a group of small non-protein coding RNAs evolutionarily conserved 142. 
MiRNAs suppress expression of gene targets at the posttranscriptional level through sequence-
specific interaction with the 3’-untranslated regions (UTR), leading to translation inhibition or 
mRNA degradation 48. Alterations in miRNA expression are found to be associated with many 
human cancers 79.  
Here we demonstrate that GRM3 expression is significantly upregulated in majority of 
human colonic adenocarcinomas tested and colon cancer cell lines. Knockdown of GRM3 
expression or pharmacological blockade of GRM3 in colon cancer cells reduces cell survival 
and anchorage-independent growth in vitro and inhibits tumor growth in vivo.  
Mechanistically, GRM3 antagonizes TGFβ-mediated activation of protein kinase A (PKA) and 
inhibition of AKT activation. In addition, TGFβ signaling increases GRM3 protein stability and 
knockdown of GRM3 expression enhances TGFβ-mediated tumor suppressor function. Further 
studies indicate that GRM3 is a direct target of miR-487b-3p and that miR-487b-3p mimics the 
effects of GRM3 knockdown in colon cancer cells in vitro and in vivo. Expression of miR-
487b-3p is decreased in colon adenocarcinomas and inversely correlates with GRM3 
expression. Taken together, these studies indicate that the miR-487b-3p/GRM3/TGFβ signaling 
axis is an important regulator of colon cancer tumorigenesis and that upregulation of GRM3 is 
a functionally important molecular event in colon cancer. Therefore, GRM3 is a promising 
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molecular target for colon cancer treatment. This is particularly interesting and important from 
a therapeutic standpoint because numerous metabotropic glutamate receptor antagonists are 
available 143(37), many of which have been found unsuitable for treatment of neuropsychiatric 
disorders due to their inability to readily penetrate blood brain barriers. Since GRM3 is 
upregulated in colon cancer, but rarely expressed in normal peripheral tissues, targeting GRM3 
with such agents would not likely cause adverse neurological or peripheral side effects, making 
GRM3 an attractive and specific molecular target for colon cancer treatment. 
RESULTS 
Expression of GRM3 is markedly increased in colon cancer specimens.  
Although it has been implicated that GRM3 is an important player in melanoma and glioma 
107, 128,120, it is unknown whether GRM3 plays a role in colon cancer. GRM3 expression was 
therefore examined in human specimens using immunohistochemistry (IHC) analysis. 
Verification of the anti-GRM3 antibody is shown in Fig. 3c. Tissue micro-arrays (TMAs) 
consisting of 29 normal colon and 65 colon adenocarcinomas were analyzed. Mouse brain 
tissue was used as a positive control. GRM3 expression was very low in normal colon 
epithelium, but increased significantly in colon tumors (Fig. 4.1a). Quantification showed that 
the average intensity of GRM3 staining and percentage of GRM3 positive cells were 
approximately 5.5-fold and 3.8-fold higher respectively in tumors than in normal colon (Fig. 
4.1b & 4.1c). In addition, GRM3 expression was increased in more than 90% of colon tumors 
examined (Fig. 4.1b & 4.1c). These results demonstrate that GRM3 expression is upregulated 
in majority of colon adenocarcinomas.  
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Fig 4.1 
 
Figure 4.1. GRM3 expression is elevated significantly in colon cancer specimens. 
a, Immunohistochemistry staining of GRM3 was performed in normal colon and colon 
adenocarcinomas. Mouse brain tissue stained with the anti-GRM3 antibody in the absence or 
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presence of a specific blocking peptide was used as a positive and negative control respectively. 
Representative images are shown. Scale bars, 100 µm. b&c, Quantification of GRM3 staining 
intensity (b) and percentage of GRM3 positive cells (c) was performed. The values of individual 
samples are shown. Error bars indicate SEM of the values. *** P < 0.001. 
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GRM3 is critical for tumor growth in vivo.  
These observations prompted us to investigate whether GRM3 plays a functional role in 
colon cancer. A panel of human colon cancer cell lines and an immortalized human colon 
epithelial cell line, HCEC119, were used. HCT116 and RKO cells are defective in TGFβ 
signaling due to lack of TGFβ RII 144. HCT116b cells were isolated from the same colon tumor 
as HCT116, but displayed much lower metastatic potential 145. FET cells, isolated from a well 
differentiated colon tumor, are sensitive to TGFβ-mediated growth inhibition and apoptosis 21. 
CBS and GEO cells are partially responsive to TGFβ due to low TGFβ RII and RI expression, 
respectively 146. HT29 cells do not express SMAD4 due to mutations 147. All cell lines bear 
either KRAS or BRAF mutations, and all except RKO 148 have mutated APC or β-catenin. 
GRM3 expression was much higher in colon cancer cells than in HCECs (Fig. 4.2a, left), 
consistent with the results from human specimens. However, GRM3 mRNA levels were similar 
between HCECs and most of colon cancer cell lines (Fig. 4.2a, middle and right), suggesting 
that upregulation of GRM3 may be through post-transcriptional mechanism(s). Of note, 
expression of GRM2, the other member of group II metabotropic glutamate receptors, was 
almost undetectable in all cell lines (Fig. 4.2a, middle). Mouse brain tissue was used as a 
positive control. These results indicate that expression of GRM3 but not GRM2 is increased in 
colon cancer cells. 
To determine GRM3 function, its expression was knocked down in FET, CBS and HCT116, 
three colon cancer cell lines with different genetic background. Each of two independent 
shRNAs (sh1 and sh2) reduced GRM3 expression by more than 90% as compared to a 
scrambled shRNA and had no effect on GRM2 expression (Fig. 4.2b, data not shown). 
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Knockdown of GRM3 increased sensitivity to growth factor deprivation stress (GFDS)-induced 
apoptosis, reflected by enhanced PARP cleavage (Fig. 4.2c) and increased apoptosis in DNA 
fragmentation assays (Fig. 4.2d). In addition, GRM3 knockdown decreased anchorage-




Figure 4.2. GRM3 expression is upregulated in colon cancer cells. 
a, GRM3 expression was determined in colon cancer cell lines and HCECs by western blot 
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analysis (left). GRM2 and GRM3 mRNA expression was determined by RT-PCR assays. 
Mouse brain tissue was used as a positive control (right). GRM3 mRNA expression was 
determined by Q-PCR assays (lower). b, GRM3 expression was knocked down by two shRNAs. 
c&d, Control or GRM3 knockdown cells were subjected to GFDS. Cleaved PARP (c) and 
apoptosis (d) were determined. e, Colony numbers were determined in soft agarose assays of 
control or GRM3 knockdown cells. f, Cell motility and migration were determined in Transwell 
assays of control or GRM3 knockdown HCT116 cells. The data are presented as the mean ± 
SD of three replications. ** P < 0.01. 
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We next examined the effect of GRM3 knockdown in vivo. Mice were subcutaneously 
injected with CBS cells stably expressing a scrambled shRNA or GRM3 shRNAs. Xenograft 
tumor growth curves showed that tumors of GRM3 shRNA-expressing cells (designated GRM3 
shRNA tumors) grew at a significantly lower rate than those of control cells (designated control 
tumors) (Fig. 4.3a). As a result, GRM3 shRNA tumors were much smaller than control tumors 
(Fig. 4.3b). IHC staining confirmed GRM3 knockdown in GRM3 shRNA tumors and verified 
the specificity of the anti-GRM3 antibody (Fig. 4.3c). TUNEL and Ki67 staining showed much 
more apoptotic cells and fewer proliferative cells in GRM3 shRNA tumors than in control 
tumors (Fig. 4.3d). These results indicate that knockdown of GRM3 inhibits tumor growth in 





         
Fig 4.3 
 
Figure 4.3. GRM3 mediates tumor growth in vivo. a, Xenograft tumor growth curves of CBS 
control and GRM3 shRNA-expressing cells are shown. n=16. b, Images of tumors at the 
endpoint of experiments are shown. The pictures were taken on the same scale with the ruler 
with each tumor (Fig. S9). c, Representative images of GRM3 staining in xenograft tumors are 
shown (left). Quantification of staining intensity and percentage of GRM3 positive cells was 
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performed (right). d, Representative images of TUNEL and Ki67 staining are shown (upper). 
Percentage of positive staining cells was determined (lower). Scale bars, 100 µm. The data are 
presented as the mean ± SD. *P < 0.05, ** P < 0.01.  
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A GRM3 antagonist mimics GRM3 knockdown in vitro and in vivo.  
LY341495 is a potent and selective antagonist of GRM2/3 149. As shown in Fig. 4a a, 
LY341495 reduced colony formation of HCT116 cells in soft agar. When mice subcutaneously 
injected with HCT116 cells were treated with LY341495, tumors grew at a slower rate than 
those treated with vehicle control (Fig. 4.4b). Therefore, tumors were markedly smaller in 
LY341495-treated group than in control group (Fig. 4.4c). TUNEL and Ki67 staining showed 
that LY341495 increased apoptotic cells and decreased proliferative cells (Fig. 4.4d). These 
results indicate that pharmacological blockade of GRM3 reduces anchorage-independent 
growth in vitro and tumor growth in vivo. 
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Fig 4.4 
 
Figure 4.4. The GRM3 antagonist inhibits tumor growth in vivo. a, Colony numbers were 
determined in soft agarose assays of control or LY341495-treated HCT116 cells. b, Xenograft 
tumor growth curves of HCT116 cells treated with LY341495 or vehicle are shown. n=14. c, 
Images of tumors at the endpoint of experiments are shown. d, Representative images of 
TUNEL and Ki67 staining are shown (left). Percentage of positive staining cells was 
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determined (right). Scale bars, 100 µm. The data are presented as the mean ± SD. *P < 0.05, 
** P < 0.01.  
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GRM3 antagonizes TGFβ to regulate cell survival through the PKA/AKT signaling axis. 
GRM3 is negatively coupled to adenylyl cyclase, inhibiting production of cAMP. Since 
cAMP activates PKA, which inhibits AKT activation, activation of PKA and AKT was 
determined. PKA activity assays showed that knockdown of GRM3 increased PKA activity 
(Fig. 4.5a). Phosphorylation of CREB, a target of PKA 150, was also used to indicate PKA 
activity. Knockdown of GRM3 increased pCREB and decreased pAKT (Fig. 4.5b, left and Fig. 
4.5c). Treatment with LY341495 or forskolin, a PKA activator, showed similar effect (Fig. 4.5b, 
middle). Complementarily, overexpression of GRM3 reduced pCREB and increased pAKT 
(Fig. 4.5b, right). These results indicate that GRM3 inhibits PKA and activates AKT in colon 
cancer cells.  
To determine whether PKA is involved in GRM3-mediated cell survival, the PKA catalytic 
α subunit (PKACα) was knocked down in FET cells 151. GRM3 knockdown-induced PKA 
activation and AKT inhibition were abrogated (Fig. 4.5d, right). Consequently, knockdown of 
PKACα attenuated GRM3 knockdown-mediated increase of apoptosis under GFDS (Fig. 4.5e). 
These results indicate that GRM3 knockdown inhibits AKT and suppresses cell survival 
through PKA activation.  
Unlike GRM3’s coupling to cAMP, TGFβ activates PKA independent of cAMP, which 
inhibits AKT and suppresses cell survival. We confirmed TGFβ effect on pCREB and pAKT in 
FET cells (Fig. 4.5d, left). Since GRM3 knockdown and TGFβ activate PKA independently, we 
determined whether combination of both would further activate PKA and inhibit AKT. The 
results showed that GRM3 knockdown and TGFβ treatment concomitantly led to additional 
increase in pCREB and decrease in pAKT (Fig. 4.5d, left).  As a result, when cells were treated 
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with TGFβ under GFDS for 14 hours, TGFβ had little effect in control cells but induced 
apoptosis in GRM3 knockdown cells (Fig. 4.5f). In addition, GRM3 knockdown sensitized FET 
cells to TGFβ-mediated inhibition of anchorage-independent growth (Fig. 4.5g). These results 
indicate that GRM3 antagonizes TGFβ-mediated tumor suppressor function and that GRM3 
knockdown enhances TGFβ effects. 
To determine the mechanism underlying collaborative effect of TGFβ and GRM3 
knockdown on PKA/AKT activation, cell survival and anchorage-independent growth, we 
investigated whether GRM3 mediates TGFβ signaling and found that GRM3 knockdown had 
no effect on expression of SMAD2, SMAD3, SMAD4 or on canonical TGFβ signaling (data 
not shown). However, TGFβ increased GRM protein expression in FET and CBS cells (Fig. 
4.5h, left and middle) while had little effect on GRM3 mRNA (Fig. 5i). Inactivation of TGFβ 
signaling by a dominant negative TGFβ RII (DNRII) in FET cells abrogated TGFβ effect on 
GRM3 expression (Fig. 4.5h, right). Time course experiments showed that TGFβ increased 
GRM3 expression as early as 30 minutes (Fig. 4.5j), suggesting that TGFβ may increase GRM3 
protein stability. Treatment with cycloheximide indicated that TGFβ markedly increased the 
half-life of GRM3 protein (Fig. 4.5k). Moreover, knockdown of SMAD2 or SMAD3 attenuated 
TGFβ-induced GRM3 protein expression but had little effect on GRM3 mRNA levels (Fig. 
4.5l), indicating that SMAD2/3 contributes to TGFβ-mediated GRM3 protein expression. 
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Fig 4.5 
 
Figure 4.5. GRM3 antagonizes TGFβ-mediated activation of PKA/AKT. a, PKA activity 
was determined in FET, HCT116 and CBS cells. b, pCREB, and pAKT were determined in 
FET control and GRM3 knockdown cells (left), FET cells treated with LY341495 or forskolin 
(middle) and vector- or GRM3-expressing FET cells (right). c&d, pCREB, and pAKT were 
determined in HCT116 and CBS control and GRM3 knockdown cells (c) and FET control and 
PKACα KD cells each infected with GRM3 sh2 or treated with 4 ng/ml TGFβ or both (d). e, 
PKACα was knocked down in FET control or GRM3 knockdown cells. Cells were subjected 
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to GFDS for 24 hrs. Cleaved PARP (upper) and apoptosis (lower) were determined. f, FET 
control or GRM3 knockdown cells were treated with 4 ng/ml TGFβ under GFDS for 14 hrs. 
Cleaved PARP (upper) and apoptosis (lower) were determined. g, Colony numbers were 
determined in soft agarose assays of FET control or GRM3 knockdown cells treated with 0.5 
ng/ml TGFβ. h, Cells were treated with 4 ng/ml TGFβ for 6 hrs. GRM3 expression was 
determined by western blot assays. i, FET cells were treated with 4 ng/ml TGFβ for 6 hrs. 
GRM3 mRNA was determined by RT-PCR assays. j, FET cells were treated with 4 ng/ml TGFβ 
for the indicated time. GRM3 expression was determined by western blot assays. k, FET cells 
were treated with cycloheximide in the presence or absence of TGFβ. GRM3 expression was 
determined by western blot assays. l, Expression of Smad2 or Smad3 was knocked down 
individually in FET cells (left). Cells were treated with TGFβ. GRM3 protein and mRNA 
expression was determined by western blot assays (middle) and RT-PCR analysis (right) 




         
MiR-487b-3p regulates GRM3 expression in colon cancer cells.  
Although TGFβ increases GRM3 expression (Fig. 4.5h), it cannot fully explain ubiquitous 
upregulation of GRM3 expression in colon cancer cell lines regardless of their response to 
TGFβ signaling (Fig. 4.2a, left). Since GRM3 expression may be regulated post-
transcriptionally (Fig. 4.2a), we turned our attention to miRNAs, which function as post-
transcriptional regulators of mRNA expression and/or translation. In the previous study we have 
identified several miRNAs that are potential regulators of TGFβ and colon cancer. We 
performed an in silico search for putative miRNA-binding sites in the 3’UTR of human GRM3 
mRNA using TargetScan 152, PicTar 153 and miRanda-mirSVR154. Among miRNA candidates 
conserved between human and mouse, miR-487b-3p was identified as a potential regulator of 
GRM3. Q-PCR assays indicated that expression of miR-487b-3p was much lower in colon 
cancer cell lines than in HCECs (Fig. 4.6a), suggesting that decreased miR-487b-3p expression 
may contribute to upregulated GRM3 expression in colon cancer cells.  
 To demonstrate that miR-487b-3p regulates GRM3 expression, miR-487b precursor was 
stably infected into FET and CBS cells. As a result, expression of mature miR-487b-3p was 
significantly increased (Fig. 4.6b, left). Complementarily, a chemically synthesized miR-487b-
3p inhibitor markedly reduced endogenous miR-487b-3p expression (Fig. 4.6b, right). 
Overexpression of miR-487b-3p decreased GRM3 protein expression whereas the inhibitor 
increased GRM3 protein expression (Fig. 4.6c, left). However, GRM3 mRNA expression was 
not affected (Fig. 4.6c, right). These results indicate that miR-487b-3p suppresses GRM3 
expression by inhibiting its translation. To determine whether GRM3 is a direct target of miR-
487b-3p, 3’-UTRs of GRM3 containing potential miR-487b-3p recognition element or mutated 
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seed sequence (Fig. 4.6d, left) was cloned into a luciferase construct. Luciferase assays revealed 
that miR-487b-3p repressed wild type but not mutant 3’-UTRs of GRM3 (Fig. 4.6d, right). 
These results indicate that GRM3 is a direct target of miR-487b-3p. Of note, miR-487b-5p did 
not target GRM3 (Fig. 4.10). 
MiR-487b-3p regulates PKA/AKT activation and mimics GRM3 knockdown effect in 
colon cancer cells.  
Similar to GRM3 knockdown, miR-487b-3p enhanced PKA activity (Fig. 4.6e), increased 
pCREB and decreased pAKT (Fig. 4.6f). MiR-487b-3p-expressing cells displayed increased 
apoptosis under GFDS (Fig. 4.6g) and decreased anchorage-independent growth (Fig. 4.6h 
and ), indicating that miR-487b-3p mimicked the effect of GRM3 knockdown. In contrast, the 
miR-487b-3p inhibitor decreased GFDS-induced apoptosis (Fig. 4.6i).   
To determine whether miR-487b-3p-mediated effect could be reversed by restoration of 
GRM3 expression, GRM3 cDNA was infected into miR-487b-3p-expressing cells (Fig. 4.6j). 
Ectopically expressed GRM3 is resistant to miR-487b-3p inhibition due to the lack of 3’-UTR. 
Restored GRM3 expression reversed miR-487b-3p-mediated increase of apoptosis (Fig. 4.6k).  
These results indicate that miR-487b-3p sensitizes colon cancer cells to GFDS-induced 
apoptosis through down-regulation of GRM3. 
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Fig 4.6  
 
Figure 4.6. GRM3 is a direct target of miR-487b-3p. a, Expression of miR-487b-3p was 
determined in HCECs and colon cancer cells by Q-PCR assays. b, Expression of miR-487b-3p 
was determined after infection with miR-487b precursor (left) or transfection with the miR-
487b inhibitor (right). c, GRM3 expression was determined by western blot assays (left) and 
by RT-PCR assays (right) after infected with miR-487b precursor or transfected with the miR-
487b-3p inhibitor. d, The predicted miR-487b-3p recognition site in the 3’UTR of GRM3 and 
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corresponding mutated sequences are indicated by lines (left). After transfection with psiCheck-
2 constructs containing the wild type (Wt) or mutant (Mut) sequences, luciferase assays were 
performed in FET control and miR-487b-3p expressing cells (right). e, PKA activity was 
determined in colon cancer cells. f, pCREB and pAKT were determined in vector- or miR-
487b-3p-expressing FET and CBS cells. g, Vector- or miR-487b-3p-expressing FET and CBS 
cells were subject to GFDS for 24 and 48 hrs respectively. Cleaved PARP (upper) and apoptosis 
(lower) were determined. h, Colony numbers were determined in soft agarose assays of vector- 
or miR-487b-3p-expressing FET and CBS cells. i, FET and HCT116b cells transfected with the 
miR-487b-3p inhibitor were subjected to GFDS for 24 or 48 hrs respectively. Cleaved PARP 
(upper) and apoptosis (lower) were determined. j&k, GRM3 was ectopically expressed in miR-
487b-3p-expressing FET and CBS cells (j), which were subjected to GFDS for 24 and 48 hrs 
respectively. Cleaved PARP (k, upper) and apoptosis (k, lower) were determined. The data are 
presented as the mean ± SD of three replications. ** P < 0.01, *** P < 0.001. 
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 To demonstrate that miR-487b-3p enhances TGFβ-mediated tumor suppressor function, 
FET cells were treated with TGFβ under GFDS for 14 hours. TGFβ induced apoptosis in miR-
487b-3p-expressing cells but not in control cells (Fig. 4.7a). In addition, TGFβ inhibited 
anchorage-independent growth by 96% in miR-487b-3p-expressing cells but only by 50% in 
control cells (Fig. 4.7b). Restoration of GRM3 expression reversed miR-487b-3p-mediated 
sensitization to TGFβ-induced apoptosis (Fig. 4.7c). Complementarily, FET cells were treated 
with TGFβ under GFDS for 24 hours. While TGFβ induced apoptosis in control cells, the miR-
487b-3p inhibitor attenuated TGFβ-induced apoptosis (Fig. 4.7d). These results indicated that 
miR-487b-3p enhances TGFβ-induced apoptosis by repressing GRM3 expression and that 
inhibition of miR-487b-3p antagonizes TGFβ effect. 
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Fig 4.7 
 
Figure 4.7. MiR-487b-3p mimics the effect of GRM3 knockdown in colon cancer cells. a, 
Vector- or miR-487b-3p-expressing FET cells were treated with 4 ng/ml TGFβ under GFDS for 
14 hrs. Cleaved PARP (left) and apoptosis (right) were determined. b, Colony numbers were 
determined in soft agarose assays of vector- or miR-487b-3p-expressing FET cells treated with 
0.5 ng/ml TGFβ. c, MiR-487b-3p-expressing FET cells were infected with GRM3 cDNA and 
treated with 4 ng/ml TGFβ under GFDS for 14 hrs. Cleaved PARP (left) and apoptosis (right) 
were determined. d, FET cells transfected with the miR-487b-3p inhibitor were treated with 4 
ng/ml TGFβ under GFDS for 24 hrs. Cleaved PARP (left) and apoptosis (right) were determined. 
The data are presented as the mean ± SD of three replications. * P < 0.05, ** P < 0.01. 
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MiR-487b-3p inhibits tumor growth in vivo.  
To determine the function of miR-487b-3p in vivo, athymic nude mice were 
subcutaneously inoculated with CBS control or miR-487b-3p-expressing cells. Xenograft 
tumor growth curves indicated that tumors of control cells (designated control tumors) grew at 
a significantly higher rate than those of miR-487b-3p-expressing cells (designated miR-487b-
3p tumors) (Fig. 4.8a). Consequently, control tumors were much bigger than miR-487b-3p 
tumors (Fig. 4.8b). Analysis of GRM3 expression showed that the intensity of GRM3 staining 
and percentage of GRM3 positive cells were notably lower in miR-487b-3p tumors than in 
control tumors (Fig. 4.8c). Moreover, TUNEL and Ki67 staining indicated more apoptotic cells 
and fewer proliferative cells in miR-487b-3p tumors than in control tumors (Figs. 4.8d & 4.8e). 
These results demonstrate that miR-487b-3p suppresses GRM3 expression and inhibit tumor 
growth in vivo.  
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Fig 4.8 
 
Figure 4.8. MiR-487b-3p suppresses GRM3 expression and inhibits tumor growth in 
vivo. a, Xenograft tumor growth curves of CBS control and miR-487b-3p-expressing cells is 
shown. n=16. b, Representative images of tumors at the endpoint of experiments are shown. 
The pictures were taken on the same scale with the ruler with each tumor (Fig. S10). c, 
Representative images of GRM3 staining in xenograft tumors are shown (upper). 
Quantification of staining intensity and percentage of GRM3 positive cells was performed 
(lower). d&e, Representative images of TUNEL (d) and Ki67 (e) staining are shown (left). 
Percentage of positive TUNEL (d) and Ki67 (e) staining cells were determined (right). Scale 
bars, 100 µm. The data are presented as the mean ± SD. *P < 0.05, ** P < 0.01. f, A proposed 
model of crosstalk between miR-487b-3p, GRM3 and TGFβ signaling in regulation of 
PKA/AKT activation, cell survival, proliferation and tumorigenesis of colon cancer cells.   
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Expression of miR-487b-3p is decreased in colon cancer specimens.  
To explore clinical relevance of miR-487b-3p, its expression was determined by in situ 
hybridization in the same sets of TMAs utilized in Figure 1. The staining intensity of miR-
487b-3p was much stronger in miR-487b-3p-expressing tumors than in control tumors (Fig. 
4.9a), verifying the specificity of the probe. Analysis of TMAs indicated that miR-487b-3p 
expression was very high in normal colon epithelium, but decreased markedly in colon tumors 
(Fig. 4.9b). Quantification of staining showed that the average intensity was significantly lower 
in colon adenocarcinomas than in normal colon (Fig. 4.9c), which is consistent with results 
from TCGA databases (Fig. 4.11). In addition, the correlation study revealed a significant 
inverse correlation between miR-487b-3p and GRM3 expression (Fig. 9d, *** P = 0.0003). 
These results demonstrate that miR-487b-3p expression is decreased in colon adenocarcinomas 
and that miR-487b-3p expression is inversely correlated with GRM3 expression.  
 Taken together, our studies suggest a novel model of crosstalk between miR-487b-3p, 
GRM3 and TGFβ signaling (Fig. 4.8f). In this model, while miR-487b-3p inhibits GRM3 
translation, TGFβ increases GRM3 protein stability as a negative feedback mechanism to 
antagonize TGFβ-induced PKA activation, AKT inhibition and suppression of cell survival, 
proliferation and tumorigenesis. Therefore, inhibition of GRM3 or expression of miR-487b-3p 
prevents this negative feedback and enhances TGFβ-mediated tumor suppressor function.  
  
55 
         
Fig 4.9 
 
Figure 4.9. Expression of miR-487b-3p is decreased in colon cancer specimens. In situ 
hybridization analysis of miR-487b-3p was performed in xenograft tumors and human 
specimens. a, Representative images of miR-487b-3p staining in xenograft tumors are shown. 
Scale bars, 100 µm. b, Normal colon in the absence of the probe was used as a negative control. 
Representative images of miR-487b-3p staining in normal colon and colon tumors are shown. 
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Scale bars, 100 µm. c, Quantification of the staining intensity was performed. The values of 
individual samples are shown. Error bars indicate SEM of the values. ** P < 0.01. d, Correlation 
of expression of miR-487b-3p and GRM3 was determined using Pearson's test (r = -0.439, *** 
P = 0.0003; n = 64). The slope was generated by lineage regression analysis. 
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Fig. 4.10. FET cells were transfected with miR-487b-5p mimic. GRM3 expression was 
















Fig. 4.11. Comparison of miR-487b-3p expression between normal colon and colon tumor 
samples was performed by analyzing UNC-H_miRNA 8X15K level 3 dataset from TCGA 









Fig. 4.12. RT-PCR analysis of GRM4 mRNA expression in HCECs and colon cancer cell lines. 





         
Fig 4.13 
 
Fig. 4.13. a, Comparison of percentage of GRM3 positive cells in well-, moderately- and 
poorly-differentiated colon tumors. The values of individual samples are shown. Error bars 
indicate SEM of the values. * P < 0.05. b, Immunohistochemistry staining of GRM3 was 
performed in normal pancreas and pancreatic tumors. Representative images are shown. Scale 
bars, 100 µm. c, Quantification of GRM3 staining intensity (left) and percentage of GRM3 
positive cells (right) was performed. The values of individual samples are shown. Error bars 
indicate SEM of the values. *** P < 0.001. 
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Fig 4.14 
 
Fig. 4.14. Western blot analysis of pERK and ERK in GRM3 knockdown (a) and miR-487b-
3p-expressing cells (b).  
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Fig 4.15 
 
Fig. 4.15. a. Control and GRM3 knockdown cells were treated with 5 ng/ml BMP. 
Phosphorylation of Smad1/5 was determined. b, FET and HCT116 cells were treated with 5 




         
DISCUSSION 
Although GRM3 protein expression is considerably higher in colon adenocarcinomas than 
in normal colon (Fig. 4.1), analysis of TCGA databases reveals that GRM3 mRNA remains 
unchanged (data not shown). It suggests that GRM3 upregulation is mediated at the 
posttranscriptional level. While transcriptional regulation of GRM3 has been reported 155-157, 
our findings that miR-487b-3p directly targets GRM3 to suppress its translation and that TGFβ 
increases GRM3 protein stability provide novel mechanisms of posttranscriptional regulation 
of GRM3 in colon cancer. Of note, GRM2, the other group II metabotropic glutamate receptor, 
and GRM4, reported to be present in colon cancer cells118, are barely expressed in colon cancer 
cells used in the study (Fig. 4.2a and Fig. 4.12), suggesting that they may not play a role in 
colon cancer. 
When correlating GRM3 expression with clinicopathological features of tumors, no 
significant correlation was found between GRM3 expression and tumor grades or stages (data 
not shown). However, percentage of GRM3 positive cells is noticeably higher in poorly-
differentiated tumors than moderately-differentiated ones (Fig. 4.13a). Due to small sample size 
of well-differentiated tumors, the difference between well-differentiated tumors and 
moderately- or poor-differentiated ones is not significant. In addition, GRM3 expression is 
significantly higher in pancreatic tumors than in normal pancreas (Fig. 4.13b and 4.13c), 
indicating that upregulation of GRM3 expression is not specific to colon cancer.  
It has been shown that mGluRs, such as GRM1 and mutant GRM3, activate the MEK 
pathway in nervous and melanoma cells 77,117. In this study, we show that GRM3 knockdown 
activates PKA and inhibits AKT in colon cancer cells. In addition, GRM3 knockdown or 
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overexpression of miR-487b-3p also decreases ERK activity (Fig. 4.14). It indicates that GRM3 
can activate multiple cancer-related signaling pathways and that the components of the 
glutamatergic system are active in colon cancer cells. Although we show that GRM2 expression 
is not upregulated in colon cancer cells, it remains to be determined whether other glutamate 
receptors or other elements of glutamate signaling are aberrantly expressed in colon cancer.  
Our studies indicate that GRM3 antagonizes TGFβ-mediated tumor suppressor effect and 
that TGFβ increases GRM3 protein stability in a Smad2/3-dependent manner. These results 
suggest that there is a negative feedback regulation between GRM3 and TGFβ signaling (Fig. 
4.8f). This is of significance since TGFβ is a major tumor suppressor in colon cancer. The 
negative feedback regulation between TGFβ and GRM3 could potentially prevent efficient 
intervention of tumor growth and progression by TGFβ signaling. In addition, it will be 
interesting to investigate whether TGFβ increases GRM3 expression in cancers where TGFβ 
functions as a tumor promoter (i.e. breast cancer). If so, given that GRM3 activates AKT and 
MEK signaling pathways, GRM3 could potentially contribute to TGFβ-mediated tumor 
promoting function (i.e. EMT, etc).  Therefore, inhibition of GRM3 could not only enhance 
TGFβ-mediated tumor suppressor function but also counteract TGFβ-mediated tumor 
promoting function, making targeting GRM3 an efficient anti-cancer approach despite of dual 
function of TGFβ signaling. Furthermore, GRM3 can also function independently of TGFβ 
signaling since GRM3 knockdown in HCT116 cells with defective TGFβ signaling increased 
apoptosis and reduced anchorage-independent growth (Fig. 4.2). Hence, GRM3 can be a 
promising molecular target in colon cancer defective of TGFβ signaling, which occurs in 30-
40% of colon cancer patients.  
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It has been reported that GRM3 negatively regulates BMP signaling in glioma cells 128. 
However, we found that GRM3 knockdown did not activate BMP signaling in colon cancer 
cells (Fig. 4.15a). In addition, unlike TGFβ, BMP treatment did not increase GRM3 expression 
(Fig. 4.15b). These results suggest that BMP signaling is not likely involved in the effects 
mediated by GRM3 knockdown and in the regulation of GRM3 expression. 
Taken together, we have identified a signaling axis, miR-487b-
3p/GRM3/TGFβ/PKA/AKT, as an important regulator of tumorigenesis in colon cancer. Our 
studies suggest that GRM3 could be a novel molecular target for colon cancer treatment. 
However, one concern to target glutamate signaling for cancer treatment is whether it would 
affect brain or neuron function. A significant amount of work has gone into designing and 
testing of drugs to modulate glutamatergic system to treat neurological and psychiatric 
disorders. Pharmaceutical companies have generated libraries of compounds that are not 
optimal for treating neuropsychiatric disorders due to problems such as inability to readily 
penetrate blood brain barriers. However, those compounds could be ideal agents for other 
applications, for example, anti-cancer therapy. Since GRM3 is mainly upregulated in colon 
cancer but rarely expressed in normal peripheral tissues, targeting GRM3 with such agents 
would not likely cause adverse neurological or peripheral side effects, making GRM3 an 
attractive and specific target for colon cancer treatment. 
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CHAPTER 5 ： MICRORNA-656-3P/VGLUT3 CROSSTALKS WITH TGFΒ 
SIGNALING TO REGULATE COLON CANCER TUMORIGENESIS 
INTRODUCTION 
Colon cancer is the second leading cause of cancer death in the US, primarily due to 
metastatic disease 1(1). Treatment of metastatic colon cancer with molecule-targeting drugs has 
not had a large clinical impact; therefore, there is an urgent need to identify new molecule 
targets and develop novel target-specific therapies.  
Glutamate is the predominant excitatory neurotransmitter in the central nervous system. In 
nervous glutamate is sorted in the synaptic vesicle before release to synaptic cleft 92. In 
mammals, two group of glutamate transport are responsible for maintaining glutamatergic 
system, Sodium-dependent excitatory Amino Acid Transporters (EAATs) and the VGLUTs. 
The family of VGLUTs is comprised of three highly homologous proteins VGLUT1-3. They 
transport glutamate from the cytoplasm into the synaptic vesicles 93. In addition to the CNS, 
VGLUTs can be found in peripheral nervous system and in glutamate-secreting non-neuronal 
cells of different organs, such as the pineal gland 97, bone99  and testes100. It has been postulated 
that the peripheral glutamatergic system may use glutamate as an intercellular messenger to 
communicate with neighboring cells158.  
In this study, we show for the first time that VGLUT3 expression is upregulated in human 
colonic adenocarcinomas and colon cancer cell lines. Knockdown of VGLUT3 expression in 
colon cancer cells reduces cell survival and anchorage-independent growth in vitro and inhibits 
tumor growth in vivo.  In addition, VGLUT3 antagonizes TGFβ-mediated inhibition of AKT 
activation and suppression of cell survival and clonogenicity. Furthermore, VGLUT3 is a direct 
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target of miR-656-3p, expression of which mimics the effects of VGLUT3 knockdown in colon 
cancer cells in vitro and in vivo. Expression of miR-656-3p is downregulated in colon 
adenocarcinomas and inversely correlates with VGLUT3 expression. Taken together, these 
studies indicate that VGLUT3 maintains AKT activation and counteracts TGFβ signaling to 
regulate colon cancer tumorigenesis. It suggests that upregulation of VGLUT3 expression is a 
functionally important molecular event during colon cancer development and that VGLUT3 is 
a potential molecular target for colon cancer treatment. This is especially interesting and 
important from a therapeutic standpoint. Given that VGLUT3 is mainly present in CNS and 
upregulated in colon cancer, but rarely expressed in normal peripheral tissues, targeting 
VGLUT3 with agents that cannot penetrate blood brain barrier would therefore not likely cause 
adverse neurological or peripheral side effects, making VGLUT3 an attractive and specific 
target for colon cancer treatment. 
RESULTS 
Expression of VGLUT3 is significantly increased in colon cancer specimens. 
Aberrant glutamatergic signaling has been reported to play a role in cancer 118,127. VGLUTs 
are critical components in glutamatergic system. However, little is known of their expression 
and function in cancer. To determine whether VGLUTs may play a functional role in colon 
cancer, we examined expression of VGLUT1-3 in a panel of human colon cancer cell lines. 
HCT116 and RKO cells are defective in TGFβ signaling due to the lack of TGFβ RII 
expression144. HCT116b cells were isolated from the same primary colon tumor as HCT116 
cells, but displayed much lower metastatic potential 145. FET cells, isolated from a well 
differentiated early stage colon tumor, are sensitive to TGFβ-mediated growth inhibition and 
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apoptosis133. CBS and GEO cells are partially responsive to TGFβ due to low TGFβ RII and RI 
expression, respectively 134,146. All cell lines bear either KRAS or BRAF mutations, and all of 
them except RKO 148 have mutated APC or β-catenin. An immortalized human colon epithelial 
cell line, HCEC 119, was included as a control. RT-PCR assays indicated that VGLUT3 mRNA 
was ubiquitously expressed in HCECs and colon cancer cell lines whereas expression of 
VGLUT1 and VGLUT2 mRNA was undetectable (Fig. 5.1A, left). Western blot analysis 
showed that VGLUT3 protein expression was markedly higher in colon cancer cells than in 
HCECs (Fig. 5.1A, right). These results indicate that VGLUT1 and VGLUT2 are not expressed 
in HCECs and colon cancer cells and that VGLUT3 expression is upregulated in colon cancer 
cells as compared to immortalized colon epithelial cells. Given that VGLUT3 mRNA levels 
were similar between HCECs and most of colon cancer cell lines (Fig. 5.1A, left), it suggests 
that upregulation of VGLUT3 may be through post-transcriptional mechanism(s). 
To determine the clinical relevance and significance of VGLUT3 upregulation, we 
extended our studies to patient specimens. VGLUT3 expression was determined in normal 
colon and colonic adenocarcinomas using immunohistochemistry (IHC) staining. Verification 
of the anti-VGLUT3 antibody is shown in Fig. 5.3C. Tissue micro-arrays (TMA) consisting of 
35 normal colon and 66 colon tumors were analyzed. Mouse brain tissue was used as a positive 
control. VGLUT3 expression was very low in normal colon epithelium, but increased 
significantly in colon tumors (Fig. 5.1B). Quantification of the staining showed that the average 
intensity of VGLUT3 staining and percentage of VGLUT3 positive cells were approximately 
2.7-fold and 2.2-fold higher in tumor samples than in normal colon respectively (Fig. 5.1C). 
These results demonstrate that VGLUT3 expression is upregulated in colon tumors, suggesting 
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that VGLUT3 may play a functional role in colon cancer. When correlating VGLUT3 
expression with clinicopathological features of tumors, no significant correlation was found 
between VGLUT3 expression and tumor grade, stage and differentiation (Figure 5.9). However, 
due to small sample size of certain groups, it is difficult to draw a clear conclusion. 
Fig 5.1 
 
Figure 5.1. VGLUT3 expression is elevated in colon cancer cells and patient specimens. A, 
Expression of VGLUT1-3 mRNA was determined in a panel of colon cancer cell lines and 
HECEs by RT-PCR assays. Mouse brain tissues were used as a positive control (left). VGLUT3 
protein expression was determined by western blot analysis (right). B, Immunohistochemistry 
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staining of VGLUT3 was performed in normal colon and colon adenocarcinomas. Mouse brain 
tissues stained with the anti-VGLUT3 antibody in the absence or presence of a specific blocking 
peptide were used as a positive and negative control respectively. Representative images are 
shown. Scale bars, 100 µm. C, Quantification of VGLUT3 staining intensity (left) and 
percentage of VGLUT3 positive cells (right) was performed. The values of individual samples 




         
Knockdown of VGLUT3 expression decreases cell survival and clonogenicity of colon 
cancer cells and enhances TGFβ effect.  
To determine whether upregulation of VGLUT3 plays an important role in colon cancer, 
VGLUT3 expression was knocked down in FET, CBS and HCT116, three colon cancer cell 
lines with different genetic background. Each of two independent shRNAs (sh2 and sh3) 
reduced VGLUT3 expression markedly as compared to a scrambled shRNA control, but had no 
effect on VGLUT1 and VGLUT2 expression (Fig. 5.2A and Fig. 5.10A). Knockdown of 
VGLUT3 expression led to increased sensitivity to growth factor deprivation stress (GFDS)-
induced apoptosis, reflected by enhanced PARP cleavage (Fig. 5.2B) and 61% to 2.3-fold 
increase of apoptosis detected in DNA fragmentation assays (Fig. 5.2C). In addition, soft agar 
assays showed that reduction of VGLUT3 expression led to 34-46% decrease in colony 
formation under anchorage-independent conditions (Fig. 5.2D). These results demonstrate that 
downregulation of VGLUT3 expression decreases cell survival and clonogenecity in vitro.  
We next determined the underlying mechanisms of VGLUT3 function. It has been shown 
that glutamatergic signaling mediates the MAPK/ERK and PI3K/AKT pathways 103. Therefore, 
activation of ERK and AKT was determined using phosphorylation of ERK (pERK) and 
phosphorylation of AKT (pAKT) as respective indicators. Knockdown of VGLUT3 in FET, 
CBS and HCT116 cells resulted in decreased pAKT (Fig. 5.2E and 2F). However, it had no 
effect on pERK (Fig. 5.10B). These results indicate that VGLUT3 expression is involved in the 
activation of AKT, which is an important survival factor in colon cancer cells 133,159.  
It has been shown that TGFβ signaling activates PKA, which inhibits AKT activation and 
cell survival in colon cancer cells 151. Although knockdown of VGLUT3 expression decreased 
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pAKT, it did not affect CREB phosphorylation (Fig. 5.10C), indicating that the effect of 
VGLUT3 on AKT activation is independent of PKA. Since knockdown of VGLUT3 and TGFβ 
signaling inhibit activation of AKT independently, we determined whether combination of both 
would further repress AKT activation. The results showed that concomitant VGLUT3 
knockdown and TGFβ treatment led to a greater decrease in pAKT than seen with either 
treatment alone (Fig. 5.2E).  When cells were treated with TGFβ under GFDS for 14 hours, 
TGFβ had little effect in control cells but induced apoptosis in VGLUT3 knockdown cells (Fig. 
5.2G and 2H). In addition, knockdown of VGLUT3 also sensitized FET cells to TGFβ-mediated 
inhibition of anchorage-independent growth (Fig. 5.2I). Taken together, these results indicate 
that, in addition to activating AKT, VGLUT3 also antagonizes TGFβ-mediated tumor 
suppressor function and that knockdown of VGLUT3 enhances TGFβ effects. 
Fig 5.2  
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Figure 5.2. Knockdown of VGLUT3 sensitizes colon cancer cells to stress-induced 
apoptosis and enhances TGFβ effect. A, VGLUT3 expression was knocked down by two 
shRNAs in FET, CBS and HCT116 cells. B & C, Control or VGLUT3 knockdown cells were 
subjected to GFDS for indicated time. Western blot analysis of PARP cleavage (B) and DNA 
fragmentation assays (C) were performed. D, Colony numbers were determined in soft agarose 
assays of control or VGLUT3 knockdown cells. E, Western blot analysis showed pAKT and 
AKT in FET control and VGLUT3 knockdown cells treated with 4 ng/ml of TGFβ. F,  
Expression of pAKT and AKT in CBS and HCT116 control and VGLUT3 knockdown cells. 
G&H, FET control or VGLUT3 knockdown cells were treated with 4 ng/ml TGFβ under GFDS 
for 14 hrs. Cleaved PARP (G) and apoptosis (H) were determined. I, Colony numbers were 
determined in soft agarose assays of FET control or VGLUT3 knockdown cells treated with 0.5 




         
VGLUT3 plays a critical role in tumor growth in vivo.  
To determine VGLUT3 function in tumor growth in vivo. athymic nude mice were injected 
with HCT116 cells stably expressing a scrambled shRNA or VGLUT3 shRNAs. Xenograft 
tumor growth curves showed that tumors of VGLUT3 shRNA-expressing cells (designated 
VGLUT3 shRNA tumors) grew at a significantly lower rate than those of control cells 
(designated control tumors) (Fig. 5.3A). Consequently, VGLUT3 shRNA tumors were much 
smaller than control tumors (Fig. 5.3B). IHC staining confirmed knockdown of VGLUT3 
expression in VGLUT3 shRNA tumors and verified the specificity of the anti-VGLUT3 
antibody (Fig. 5.3C). TUNEL and Ki67 staining showed much more apoptotic cells and fewer 
proliferative cells in VGLUT3 shRNA tumors than in control tumors (Fig. 5.3D). These results 
indicate that knockdown of VGLUT3 inhibits tumor growth in vivo and that this inhibitory 




         
Figure 3. VGLUT3 mediates tumor growth of colon cancer cells in vivo. A, Xenograft tumor 
growth curves of HCT116 control and VGLUT3 shRNA-expressing cells are shown. n=16. B, 
Images of tumors at the endpoint of experiments are shown. Scale bars, 1 cm. C, Representative 
images of VGLUT3 staining in xenograft tumors are shown (upper). Quantification of staining 
intensity was performed (lower). D, Representative images of TUNEL and Ki67 staining are 
shown (upper). Percentage of positive staining cells was determined (lower). Scale bars, 100 
µm. The data are presented as the mean ± SD. *P < 0.05, ** P < 0.01, *** P < 0.001.  
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MiR-656-3p regulates VGLUT3 expression in colon cancer cells.  
Since VGLUT3 expression may be regulated post-transcriptionally, miRNAs, functioning 
as post-transcriptional regulators of mRNA expression and/or translation, could regulate its 
expression. We therefore performed an in silico search for putative miRNA-binding sites in the 
3’-UTR of the human VGLUT3 mRNA using TargetScan 152, PicTar 153 and miRanda-
mirSVR154. Among miRNA candidates conserved between human and mouse, miR-656-3p was 
identified as a potential regulator of VGLUT3. Q-PCR assays indicated that expression of miR-
656-3p was much lower in colon cancer cell lines than in HCECs (Fig. 5.4A), suggesting that 
decreased miR-656-3p expression may contribute to upregulated VGLUT3 expression in colon 
cancer cells.  
 To demonstrate that miR-656-3p regulates VGLUT3 expression, the miR-656 precursor 
was stably infected into FET, CBS and HCT116 cells. As a result, expression of mature miR-
656-3p was significantly increased (Fig. 5.4B). Complementarily, a chemically synthesized 
miR-656-3p inhibitor markedly reduced endogenous miR-656-3p expression by 40% and 43% 
in FET and HCT116 cells respectively (Fig. 5.4B). Overexpression of miR-656-3p decreased 
VGLUT3 protein expression (Fig. 5.4C) whereas the miR-656-3p inhibitor increased VGLUT3 
protein expression (Fig. 5.4D). However, VGLUT3 mRNA expression was not affected (Fig. 
5.4E). These results indicate that miR-656-3p suppresses VGLUT3 expression by inhibiting its 
translation. To determine whether VGLUT3 is a direct target of miR-656-3p, three sequences 
in the 3’-UTRs of VGLUT3 containing the potential miR-656-3p recognition element (Fig. 
5.4F) was cloned into a luciferase construct. Luciferase assays revealed that miR-656-3p 
repressed site 1 but not site 2 or site 3 of 3’-UTRs of VGLUT3 (Fig. 5.4G). These results 
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indicate that miR-656-3p directly targets VGLUT3 partially through binding to site 1 to inhibit 
its translation.  
MiR-656-3p inhibits AKT activation and mediates stress-induced apoptosis and 
clonogenicity in colon cancer cells.  
Similar to VGLUT3 knockdown, miR-656-3p decreased pAKT (Fig. 5.4C) but had no 
effect on ERK or PKA activation (Fig. 5.10D and 5.10E). MiR-656-3p-expressing cells 
displayed increased PARP cleavage and 48-54% increase of apoptosis under GFDS (Fig. 5.5A). 
In addition, anchorage-independent growth was reduced by 34-60% in miR-656-3p-expressing 
cells (Fig. 5.5B). These results indicate that miR-656-3p mimics the effect of VGLUT3 
knockdown. In contrast, the miR-656-3p inhibitor, which effectively inhibited miR-656-3p 
expression in FET and HCT116 cells (Fig. 5.4B), reduced PARP cleavage and decreased GFDS-
induced apoptosis by 34% and 54% respectively (Fig. 5.5C).   
  
78 
         
Fig 5.4 
 
Figure 5.4. VGLUT3 is a direct target of miR-656-3p. A, Expression of miR-656-3p was 
determined in HCECs and colon cancer cells by Q-PCR assays. B, Expression of miR-656-3p 
was determined after infection with miR-656 precursor or transfection with the miR-656-3p 
inhibitor. C&D, VGLUT3 expression was determined by western blot assays after infected with 
the miR-656 precursor (C) or transfected with the miR-656-3p inhibitor (D). Expression of 
AKT and pAKT was also determined. E, mRNA expression of VGLUT3 was determined by 
RT-PCR assays after infected with miR-656 precursor or transfected with the miR-656-3p 
inhibitor. F, The predicted miR-656-3p recognition sites in the 3’-UTR of VGLUT3 are 
indicated by vertical lines. G, After transfection with psiCheck-2 constructs containing site 1, 
2 or 3 sequences, luciferase assays were performed in FET control and miR-656-3p expressing 
cells.  
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To determine whether miR-656-3p-mediated sensitization to GFDS-induced apoptosis 
could be reversed by restoration of VGLUT3 expression, VGLUT3 cDNA was infected into 
miR-656-3p-expressing FET and HCT116 cells (Fig. 5.5D, upper). Ectopically expressed 
VGLUT3 is resistant to down-regulation mediated by miR-656-3p due to the lack of 3’-UTR. 
Ecotopic VGLUT3 expression reversed miR-656-3p-mediated increase of apoptosis under 
GFDS (Fig. 5.5D).  These results indicate that miR-656-3p sensitizes colon cancer cells to 
GFDS-induced apoptosis through the down- regulation of VGLUT3 expression. 
To investigate whether miR-656-3p enhances TGFβ-mediated tumor suppressor function, 
FET cells were treated with TGFβ under GFDS for 14 hours. TGFβ induced apoptosis in miR-
656-3p-expressing cells but not in control cells (Fig. 5.5E). In addition, TGFβ inhibited 
anchorage-independent growth by 61% in miR-656-3p-expressing cells but only by 30% in 
control cells (Fig. 5.5F). Complementarily, FET cells were treated with TGFβ under GFDS for 
24 hours. While TGFβ induced apoptosis in control cells, the miR-656-3p inhibitor significantly 
attenuated TGFβ-induced apoptosis (Fig. 5.5G). These results indicated that miR-656-3p 
enhances TGFβ-induced apoptosis and that inhibition of miR-656-3p antagonizes TGFβ effect.  
  
80 
         
Fig 5.5 
 
Figure 5.5. MiR-656-3p mimics the effect of VGLUT3 knockdown in colon cancer cells. A, 
Vector- or miR-656-3p-expressing FET, CBS and HCT116 cells were subject to GFDS for 
indicated time. Cleaved PARP (left) and apoptosis (right) were determined. B, Colony numbers 
were determined in soft agarose assays of vector- or miR-656-3p-expressing cells. C, FET and 
HCT116 cells transfected with the miR-656-3p inhibitor were subjected to GFDS for 24 or 72 
hrs respectively. Western blot analysis of cleaved PARP (left) and DNA fragmentation assays 
(right) were determined. D, VGLUT3 was ectopically expressed in miR-656-3p-expressing 
FET and HCT116 cells (upper), which were subjected to GFDS for 24 and 72 hrs respectively. 
Cleaved PARP (upper) and apoptosis (lower) were determined. E, Vector- or miR-656-3p-
expressing FET cells were treated with 4 ng/ml TGFβ under GFDS for 14 hrs. Cleaved PARP 
(left) and apoptosis (right) were determined. F, Colony numbers were determined in soft 
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agarose assays of vector- or miR-656-3p-expressing FET cells treated with 0.5 ng/ml TGFβ. G, 
FET cells transfected with the miR-656-3p inhibitor were treated with 4 ng/ml TGFβ under 
GFDS for 24 hrs. Cleaved PARP (left) and apoptosis (right) were determined. The data are 
presented as the mean ± SD of three replications. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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MiR-656-3p inhibits tumor growth in vivo.  
We next determine the function of miR-656-3p in vivo. Athymic nude mice were 
subcutaneously inoculated with HCT116 control or miR-656-3p-expressing cells. Xenograft 
tumor growth curves showed that tumors of miR-656-3p-expressing cells (designated miR-656-
3p tumors) grew at a significantly lower rate than those of control cells (designated control 
tumors) (Fig. 5.6A). Consequently, miR-656-3p tumors were much smaller than control tumors 
(Fig. 5.6B). Analysis of VGLUT3 expression showed that the intensity of VGLUT3 staining 
was notably lower in miR-656-3p tumors than in control tumors (Fig. 5.6C). Furthermore, 
TUNEL and Ki67 staining indicated more apoptotic cells and fewer proliferative cells in miR-
656-3p tumors than in control tumors (Fig. 5.6D). These results demonstrate that miR-656-3p 
suppresses VGLUT3 expression, increases apoptosis, decreases proliferation and inhibit tumor 
growth in vivo.  
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Fig 5.6 
 
Figure 5.6. MiR-656b-3p suppresses VGLUT3 expression and inhibits tumor growth in 
vivo. A, Xenograft tumor growth curves of HCT116 control and miR-656-3p-expressing cells 
is shown. n=16. B, Images of tumors at the endpoint of experiments are shown. Scale bars, 1 
cm. C, Representative images of VGLUT3 staining in xenograft tumors are shown (left). 
Quantification of staining intensity was performed (right). D, Representative images of TUNEL 
and Ki67 staining are shown (left). Percentage of positive TUNEL and Ki67 staining cells were 
determined (right). Scale bars, 100 µm. The data are presented as the mean ± SD. *P < 0.05, 
** P < 0.01.  
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Expression of miR-656-3p is decreased in colon cancer specimens.  
To explore clinical relevance of miR-656-3p, its expression was determined by in situ 
hybridization in the same sets of TMAs utilized in Figure 1. The staining intensity of miR-656-
3p was much stronger in miR-656-3p-expressing tumors than in control tumors (Fig. 5.7A), 
verifying the specificity of the probe. Analysis of TMAs indicated that miR-656-3p expression 
was high in normal colon epithelium, but decreased markedly in colon tumors (Fig. 5.7B). 
Quantification of staining showed that the average intensity was significantly lower in colon 
adenocarcinomas than in normal colon (Fig. 5.7C). In addition, the correlation study revealed 
a moderate negative correlation between miR-656-3p and VGLUT3 expression (Fig. 5.7D, *P 
= 0.025). These results demonstrate that miR-656-3p expression is decreased in colon 
adenocarcinomas and inversely correlates with VGLUT3 expression and that downregulation 
of miR-656-3p in colon tumors is at least partially responsible for VGLUT3 upregulation.  
  
85 
         
Fig 5.7 
 
Figure 5.7. Expression of miR-656-3p is decreased in colon cancer specimens. In situ 
hybridization analysis of miR-656-3p was performed in xenograft tumors and human 
specimens. A, Representative images of miR-656-3p staining in xenograft tumors are shown. 
Scale bars, 100 µm. B, Normal colon in the absence of the probe was used as a negative control. 
Representative images of miR-656-3p staining in normal colon and colon tumors are shown. 
Scale bars, 100 µm. C, Quantification of the staining intensity was performed. The values of 
individual samples are shown. Error bars indicate SEM of the values. *** P < 0.001. D, 
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Correlation of expression of miR-656-3p and VGLUT3 was determined in colon tumors using 




         
Taken together, our studies suggest a novel model of crosstalk between miR-656-3p, 
VGLUT3, AKT and TGFβ signaling (Fig. 5.8). In this model, miR-656 downregulates 
VGLUT3 expression, which leads to AKT inhibition. On the other hand, TGFβ signaling 
activates PKA and suppresses AKT activation. Consequently, downregulation of VGLUT3 or 
expression of miR-656-3p collaborates with TGFβ signaling to inhibit AKT activation and 
enhance TGFβ-mediated tumor suppressor function whereas upregulation of VGLUT3 




Figure 5.8. A proposed model of crosstalk between miR-656-3p, VGLUT3 and TGFβ signaling 
in regulation of AKT activation, cell survival, proliferation and tumorigenesis of colon cancer 




         
Fig 5.9 
 
Fig. 5.9. Comparison of VGLUT3 intensity and percentage of VGLUT3 positive cells was 
made in low, moderate and high grade colon tumors (A), in different stages of colon tumors (B) 
and in well-, moderately- and poorly-differentiated colon tumors (C). The values of individual 
samples are shown. Error bars indicate SEM of the values. There is no significant difference 
among the groups. 
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Fig 5.10 
 
Fig. 5.10. A, RT-PCR analysis of VGLUT1-3 mRNA expression in VGLUT3 knockdown FET 
cells. Mouse brain tissues were used as a positive control. B&D, Western blot analysis of pERK 
and total ERK in VGLUT3 knockdown cells (B) and miR-656-3p expressing cells (D). C&E, 
Western blot analysis of pCREB and total CREB in VGLUT3 knockdown cells (C) and miR-
656-3p expressing cells (E). 
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Fig 5.11 
 
Fig. 5.11. Glutamate secretion was evaluated in the control and VGLUT3 knockdown cells. 
Cells were cultured in glutamine-free, glutamate-free and phenol red-free DMEM (Gibco) for 
48 hours. Conditioned medium was collected and glutamate levels were determined using 
AMPLEX Red Glutamic Acid assay kit (Invitrogen) and analyzed on a fluorescence plate reader. 
The average concentrations of glutamate per 10,000 cells are shown. Error bars indicate SD of 






         
DISCUSSION 
Glutamatergic signaling has been extensively studied in nerve cells, where they modulate 
excitatory synaptic transmission. VGLUT3, a vesicular glutamate transporter, is an unusual 
member of the VGLUT family. It is expressed not only in glutamatergic neurons but also in 
non-glutamatergic neurons such as serotonergic and cholinergic neurons and in astrocytes as 
well. In addition, its subcellular localization is not restricted to synaptic boutons, but also 
includes the cell soma and dendrites 95,96. In this study, we discover that expression of VGLUT3 
is upregulated significantly in colon tumors as compared to normal colon. Additional findings 
indicate that miR-656-3p directly targets VGLUT3 to suppress its translation and that 
downregulation of miR-656-3p in colon tumors is at least partially responsible for VGLUT3 
upregulation. Therefore, our studies provide a novel mechanism by which VGLUT3 expression 
is regulated in colon cancer. Of note, VGLUT1 and VGLUT2, two other vesicular glutamate 
transporters, are barely expressed in colon cancer cells (Fig. 5.1A), suggesting that they may 
not play a role in colon cancer.  
It has been reported that VGLUTs transport cytoplasmic glutamate into the synaptic 
vesicles, which is then released by glutamatergic neurons 93. Outside the nervous system, 
VGLUTs can be found in the glutamate-secreting non-neuronal cells of different organs, such 
as the pineal gland 97, bone 99  and testes 100. It has been proposed that this peripheral 
glutamatergic system may use glutamate as a messenger to transduce signaling in an autocrine 
or paracrine manner. We have shown that GRM3, a group II metabotropic glutamate receptor, 
is significantly upregulated in colon cancer and that knockdown or inhibition of GRM3 
activation in colon cancer cells reduces cell survival and anchorage-independent growth in vitro 
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and inhibits tumor growth in vivo 160.  These studies suggest that peripheral glutamatergic 
signaling may contribute to colon cancer development. Therefore, a potential function of 
VGLUT3 in colon cancer would be to facilitate glutamate secretion, which then activates 
GRM3 or other glutamate receptors to promote tumor growth. However, knockdown of 
VGLUT3 expression did not affect glutamate secretion in FET and HCT116 cells (Fig. 5.11), 
indicating that VGLUT3 is not involved in glutamate secretion of colon cancer cells. In addition, 
glutamate signaling, for example GRM3 activation, has been shown to activate downstream 
signaling pathways including PI3K/AKT and MAPK/ERK 103,160. Although knockdown of 
VGLUT3 inhibits AKT activation, it has no effect on ERK activity (Fig. 5.10B). It remains to 
be determined whether VGLUT3 contributes to glutamatergic signaling and how VGLUT3 
regulates AKT activation in colon cancer cells.  
Our studies indicate that VGLUT3 antagonizes TGFβ-mediated tumor suppressor effect. 
This is of significance since TGFβ is an important tumor suppressor in colon cancer 132-135. 
Upregulation of VGLUT3 could potentially prevent efficient intervention of tumor growth and 
progression by TGFβ signaling. TGFβ has been shown to activate PKA, which subsequently 
inhibits AKT activation in colon cancer cells 159. However, knockdown of VGLUT3 has no 
effect on PKA signaling, but represses AKT activation. Therefore, VGLUT3 and TGFβ 
signaling counteract each other to regulate AKT activity (Fig. 5.8). Furthermore, VGLUT3 can 
also function independently of TGFβ signaling since knockdown of VGLUT3 in HCT116 cells 
with defective TGFβ signaling led to decreased AKT activation, increased apoptosis and 
reduced anchorage-independent growth (Fig. 5.2). Therefore, VGLUT3 is a potential molecular 
target in colon cancer regardless of the status of TGFβ signaling. In addition, VGLUT3 
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expression is also markedly higher in pancreatic tumors than in normal pancreas (data not 
shown), indicating that upregulation of VGLUT3 expression is not specific to colon cancer and 
that VGLUT3 could be a prospective therapeutic target in other cancers as well. 
Taken together, we have identified a signaling axis, miR-656-3p/VGLUT3/AKT, as an 
important regulator of tumorigenesis in colon cancer. Our studies suggest that VGLUT3 could 
be a novel molecular target for colon cancer treatment. Therefore, development of VGLUT3 
inhibitors that cannot cross blood brain barriers is of clinical significance. Since VGLUT3 is 
mainly expressed in CNS and upregulated in colon cancer but rarely expressed in normal 
peripheral tissues, targeting VGLUT3 with those inhibitors will not likely cause adverse 
neurological or peripheral side effects, making VGLUT3 an attractive and specific target for 





         
CHAPTER 6: DISCUSSION AND FUTURE DIRECTIONS 
miRNAs and TGFβ 
In this study, we identified several miRNAs whose expression is either downregulated or 
upregulated after TGFβ treatment in a functional screening. We confirmed that miR-487b-3p 
and miR-656-3p modulated TGFβ function in colon cancer cells. TGFβ signaling plays multiple 
roles in different stages of cancer. During tumor progression, there are many genetic events 
occur in TGFβ signaling pathway, including the mutations of TGFβ receptor RII as well as 
SMAD proteins 24 31. However, those changes cannot fully explain the alterations in TGFβ 
signaling during tumor progression. miRNAs are important regulators of TGFβ, they modulate 
TGFβ function by targeting canonical TGFβ signaling components or regulating TGFβ target 
genes74. Both miR-487b-3p and miR-656-3p enhance TGFβ function by inhibiting AKT 
activation. However, they have no effect on canonical TGFβ signaling itself. MiR-487b-3p and 
miR-656-3p are both located at 14q32.31 locus. By analyzing TCGA data base, we found that 
loss of copy number of this region was frequently occurred in colon cancer (data not shown). 
Those data suggest that during cancer progression, decrease of those two miRNAs may 
contribute to attenuated TGFβ tumor suppressing effect in colon cancer. By analyzing the target 
genes of those miRNAs, we will be able to identify novel regulators of TGFβ signaling and 
tumor growth. 
Regulation of glutamate homeostasis in cancers 
We have demonstrated that expression of GRM3 and VGLUT3 was increased in colon 
cancer patient samples and both of them played important roles in tumorigenesis of colon cancer. 
GRM3 and VGLUT3 are both key components of glutamatergic signaling. Two decades ago, 
95 
         
people noticed that glutamate level was increased in colon cancer tissues 161. Glutamate is a 
major product of glutaminolysis in mammalian cells. Tumor cells use glutamine as a major fuel 
for their bioenergetic needs and intermediates for macromolecular synthesis. When transported 
into the cells, glutamine is rapidly converted into glutamate by phosphate-dependent 
glutaminase (GLS), which consequentially, provides materials to meet cell’s energy and 
biosynthetic needs 162.  There are many glutamate transporters that maintain intracellular and 
extracellular glutamate homeostasis. EAATs transport L-and D-aspartate along with glutamate 
from extracellular environment to the cells and maintain low level of extracellular glutamate 
163. Another transporter, Na+-independent cystine/glutamate exchanger, System xc − (SXC), 
uptakes extracellular cysteine and exports intracellular glutamate outside of the cells 164 .  In 
neurons, cytoplasmic glutamate is transported into vesicles by VGLUTs, and released into 
synaptic cleft 93.  In tumors, loss of glutamate homeostasis is usually attributed to abnormal 
expression of glutamate transporters 165. In this study, we found VGLUT3 was upregulated in 
colon cancer cells. However, knockdown of VGLUT3 did not change the extracellular 
glutamate level. Since the other two vesicular glutamate transporters, VGLUT1 and VGULT2, 
are barely expressed in colon cancer cells, other types of transporters may play major role in 
the increased level of extracellular Glutamate. People found EAAT2 mediated glutamate 
transportation was  defect in glioma tissues166. In breast cancer, high level of glutamate 
secretion is mediated by System xc – 167. In colon cancer cells, downregulation of EAAT1 and 
EAAT3 were found to be correlated with drug resistance 168. Therefore, it will be very 
interesting to find out whether EAATs and SXC are abnormally expressed in colon cancers. 
Studying their function will help understand the regulation and function of the glutamate 
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pathway during tumor development. 
Glutamate activates multiple pathways through multiple receptors 
Glutamate is a major excitatory neurotransmitter in central nervous system. In cancers, 
increasing evidence is showing its important role in tumor development. Like growth factors, 
glutamate acts through binding to a large family of receptors to active multiple downstream 
pathways. There are two types of glutamate receptors, ionotropic glutamate receptors and 
metabotropic glutamate receptors, both families have been proven to foster tumor growth in 
different cell context 102. We found that knockdown of GRM3 inhibits AKT activation and 
inhibits tumor growth of colon cancer cells both in vitro and in vivo. In addition, knockdown of 
GRM3 also inhibits ERK activation. Those results indicate GRM3 activates multiple 
downstream pathways to regulate colon cancer tumor growth. However, GRM2 and GRM4 are 
absent in our cell model and do not appear to play any role. Considering that there are more 
than 20 glutamate receptors, future efforts will determine the function of those receptors in 
colon cancer.  
Regulation of GRM3 
We showed that GRM3 was upregulated in colon cancer and that the upregulation was at 
the posttranscriptional level. We also showed that TGFβ increased GRM3 protein stability in a 
Smad2/3-dependent manner. How GRM3 is upregulated during tumor progression remains an 
interesting question. For most GPCRs, the endocytic pathway tightly controls their activity 169. 
On the cell surface, GPCRs are able to bind their ligands and activate signaling cascades inside 
the cells. After that, receptors are first phosphorylated by GPCR kinases (GRKs) and then 
internalized, which is mediated by arrestins and clathrin-coated pits. Some of the receptors are 
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recycled back to cell membrane and others are targeted to the lysosome for degradation, which 
results in the complete termination of receptor activity 169. Whether GRM3 turnover is 
dysregulated in colon cancer remains to be investigated. Defects of the recycling machinery 
will lead to increased expression of GRM3 on the cell surface and prolonged receptor activity. 
Other insights of VGLUT3 and GRM3 
VGLUTs are responsible for transporting glutamate into synaptic vesicles93. In this study, 
we found that VGLUT3 was upregulated in colon cancer, leading to increased AKT activation. 
It suggests the importance of glutamate transportation in cancer development. Surprisingly, 
knockdown of VGLUT3 in colon cancer cells does not affect the extracellular glutamate level, 
indicating that there may be other mechanisms involved in the function of VGLUT3. In 
pancreatic β cells, it was found that VGLUT3 mediated glutamate uptake into insulin containing 
secretory vesicles 170, which modulated insulin release 171. Those findings reveal that VGLUT3 
may co-transport other growth factors through the glutamate-containing vesicles. Once released 
to the extracellular environment, those growth factors may bind to their receptors and active 
various downstream signaling in cancer cells. 
Like other G protein coupled receptors, GRM3 converts extracellular signals into 
intracellular responses. However, some G protein coupled receptors are found to be localized 
on intracellular membranes, and their function is distinct from their cell surface counterparts. 
For example, more than 80% of GRM5 was found at intracellular membrane in the rat and 
monkey substantia nigra 172. Only intracellular mGluR5 is able to phosphorylate ERK1/2 and 
Elk-1173. Those findings emphasize that glutamate may activate distinct signaling pathways by 
binding to intracellular glutamate receptors. So far, there is no evidence showing that GRM3 is 
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exclusively expressed on the cell membrane. Therefore, it will be very interesting to determine 
whether GRM3 is also expressed on the membrane of other intracellular organelles. The change 
of intracellular glutamate may trigger distinct signaling pathways. Moreover, in that case, 
VGLUTs may also play a role in this process by transporting glutamate from cytoplasm to 
subcellular compartments, where glutamate binds to their receptors and activates intracellular 
glutamate signaling.  
Pharmacology of glutamate pathway inhibitors in cancer treatment  
In recent years, increasing evidence shows the importance of glutamate signaling in tumor 
development. Many glutamate receptor antagonists have been implicated to have potential for 
cancer treatment.  AMPAR/KR inhibitors, ZK 200775 and GYKI 52466 showed anti-
proliferative effect in glioma models102. An NMDAR antagonist, memantine has been 
employed in a Phase II clinical trial now 102. The glutamate release inhibitor riluzole which is 
approved by FDA for treating amyotrophic lateral sclerosis showed promising inhibitory effect 
in glioma, breast cancer and prostate cancers 174. mGluRs are considered more susceptible for 
anti-cancer drug design due to their structure –function relationship 60. However, clinical studies 
of mGluR antagonists are still lacking. In this study, we showed that a GRM3 inhibitor, 
LY341495, inhibited tumor growth of colon cancer cells in vivo. Future studies are needed to 
validate the anti-cancer effect of GRM3 antagonists in clinical trials. Since GRM3 activates 
multiple signaling pathways, combination of GRM3 antagonists with other drugs may help 
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